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1. INTRODUCTION 
The tablet is the most widely used dosage form because of its convenience in 
terms of self-administration, compactness, and ease in manufacturing. However, 
geriatric and pediatric patients experience difficulty in swallowing conventional tablets, 
which leads to poor patient compliance. 
To overcome this weakness, scientists have developed innovative drug delivery 
systems known as “melt in mouth” or “mouth dissolve (MD)” tablets. These are novel 
types of tablets that disintegrate/dissolve/disperse in saliva. 
 Their characteristic advantages such as administration without water, anywhere, 
anytime, lead to their suitability to geriatric and pediatric patients. They are also suitable 
for the mentally ill, the bedridden, and patients who do not have easy access to water.  
The benefits, in terms of patient compliance, rapid onset of action, increased 
bioavailability, and good stability, makes these tablets popular as a dosage form of 
choice in the current market. 
A broad range of drugs cardiovascular, analgesics, narcoleptics, antihistamines, 
and antibiotics can be considered candidates for this dosage form.  
Fast dissolving tablets are formulated by techniques like tablet molding, spray 
drying, lyophilization, sublimation and addition of disintegrants. Some of the patented 
technologies for preparation of fast dissolving tablets are Zydis,OraSolv, DuraSolv, 
Flash Dose, Wow tab (Without Water), and Flashtab1.    
     These are novel types of tablets that dissolve/disintegrate/ disperse in saliva within 
few seconds without water. According to European pharmacopoeia, these MDTs should 
dissolve/disintegrate in less than three minutes. The formulation is more useful for the 
bed-ridden and patients who have the swallowing problem.  
The benefits of MDTs is to improve patients compliance, rapid onset of action, 
increased bioavailability and good stability which make these tablets popular as a 
dosage form of choice in the current market.  
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Mouth dissolving tablets are also called as orodispersible tablets, fast 
disintegrating tablets, orally disintegrating tablets, quick disintegrating tablets, fast 
dissolving tablets, rapid dissolving tablets, porous tablets, quick melt tablets and rapid 
melt tablets.  
 
However, of all the above terms United States Pharmacopoeia (USP) approved 
these dosage forms as ODTs. United States Food and Drug Administration (FDA) 
defined ODTs as “A solid dosage form containing medicinal substances or active 
ingredients which disintegrates rapidly within a few seconds when placed up on 
tongue2. 
 
DEFINITION 
The Centre for Drug Evaluation and Research (CDER), US FDA defined Oral 
Disintegrating Tablets (ODT) as “A solid dosage form containing medicinal substances, 
which disintegrates rapidly, usually within a matter seconds, when placed up on the 
tongue”. FDTs disintegrate and/or dissolve rapidly in the saliva without the need for 
water.  
 
Some tablets are designed to dissolve in saliva remarkably fast, within a few 
seconds, and are true fast-dissolving tablets. Others contain agents to enhance the rate 
of tablet disintegration in the oral cavity, and are more appropriately termed fast-
disintegrating tablets, as they may take up to a minute to completely disintegrate. When 
put on tongue, this tablet disintegrates instantaneously, releasing the drug, which 
dissolves or disperses in the saliva.  
 
Some drugs are absorbed from the mouth, pharynx and oesophagus as the 
saliva passes down into the stomach. In such cases, bioavailability of drug is 
significantly greater than those observed from conventional tablet dosage form. 
 
Their growing importance was underlined recently when European 
Pharmacopoeia adopted the term “Orodispersible Tablet” as a tablet that to be placed in 
oral cavity where it disperses rapidly before swallowing. 
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SALIENT FEATURES OF FAST DISSOLVING DRUG DELIVERY SYSTEM: 
 
1. Ease of administration for patients who are mentally ill, disabled and uncooperative. 
 
2. Requires no water. 
 
3. Quick disintegration and dissolution of the dosage form. 
 
4. Overcomes unacceptable taste of the drugs.  
 
5. Can be designed to leave minimal or no residue in the mouth after administration and 
also to provide a pleasant mouth feel. 
 
6. Allows high drug loading. 
 
7. Ability to provide advantages of liquid medication in the form of solid preparation. 
Adaptable and amenable to existing processing and packaging machinery. 
 
8. Cost-effective. 
 
 
SIGNIFICANCE OF ORAL DISINTEGRATING TABLETS 
 
Oral Disintegrating Tablets offer dual advantages of solid dosage forms and liquid 
dosage forms along with special features which include: 
 
Accurate dosing - Being unit solid dosage forms, provide luxury of accurate dosing, 
easy Portability and manufacturing, good physical and chemical stability and an ideal 
alternative for pediatric and geriatric patients. 
 
Enhanced bioavailability - 
Bioavailability of drugs is enhanced due to absorption from mouth, pharynx and 
oesophagus. 
 
Rapid action – 
Fast onset of therapeutic action as tablet gets disintegrated rapidly along with quick 
dissolution and absorption in oral cavity. 
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Patient compliance - 
No need of water to swallow the dosage form. Hence, it is convenient for patient who 
are travelling and do not have immediate access to water. 
 
Ease of administration - 
Convenient to administer especially for geriatric, paediatric, mentally disabled and bed 
ridden patients who have difficulty in swallowing. 
 
Obstruction free - 
No risk of suffocation in airways due to physical obstruction when swallowed, thus 
providing improved safety and compliance. 
 
Enhanced palatability - 
Good mouths feel, especially for paediatric patients as taste masking technique is used 
to avoid the bitter taste of drug. 
 
Simple packaging - 
No specific packaging required. It can be packaged in push through blisters. 
 
Business Avenue - 
Provide new business opportunities in the form of product differentiation, line extension, 
uniqueness and life cycle management. 
 
Cost effective - 
Conventional processing and packaging equipment’s allow the manufacturing of tablets 
at low cost. 
 
CHARACTERISTICS OF FAST DISSOLVING DELIVERY SYSTEM 
1. Ease of administration: Fast Dissolving Delivery Systems are easy to administer 
and handle hence, leads to better patient compliance. Usually, elderly people 
experience difficulty in swallowing the conventional dosage forms (tablets, capsules, 
and dysphasia. 
 
2. Taste of the medicament: As most drugs are unpalatable, mouth dissolving delivery 
systems usually contain the medicament in taste masked form. Delivery systems 
dissolve or disintegrate in patient’s mouth, thus releasing the active ingredients which 
come in contact with the taste bud and hence, masking of the drugs becomes critical to 
patient compliance. 
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3. Hygroscopicity: Several fast dissolving dosage forms are hygroscopic and cannot 
maintain physical integrity under normal condition from humidity which called for special 
packaging. 
 
4. Friability: In order to allow fast dissolving tablets to dissolve in the mouth, they are 
made of either very porous and soft-molded matrices or compressed into tablets with 
very low compression force, which makes the tablets friable and/or brittle which are 
difficult to handle, often requiring specialized peel-off blister packaging. 
 
5. Mouth feel: Mouth feel is critical, and patients should receive a product that feels 
pleasant. Any large particles from the disintegrating tablet that are insoluble or slowly 
soluble in saliva would lead to an unpleasant gritty feeling. This can be overcome by 
keeping the majority of the particles below the detectable size limit     3. 
 
BENEFITS OF FAST DISSOLVING TABLETS: 
 Administered without water, anywhere, any time. 
 
 Suitability for geriatric and pediatric patients, who experience difficulties in 
swallowing and for the other groups that may experience problems using 
conventional oral dosage form, due to being mentally ill, the developmentally 
disable and the patients who are uncooperative, or are on reduced liquid intake 
plans or are nauseated. 
 
 An increased bioavailability, particularly in cases of insoluble and hydrophobic 
drugs, due to rapid disintegration and dissolution of these tablets.  
 
COMMON CONDITIONS FOR ODTS INDICATIONS   
 Pain, fever, heartburn, diarrhea, migraine, anxiety, insomnia for fast faction.  
 
 Parkinson’s disease, Alzheimer’s disease, psychosis, Schizophrenia, 
Hypertension, Cholesterol, Transplantation to improve patient’s compliance. 
 
 Cough, cold, allergy, pain, fever, ADHD that can be associated with pediatrics4.  
 
ADVANTAGES OF ODTS AS DRUG DELIVERY SYSTEM 4, 5, 6  
 Pregastric absorption from the mouth, pharynx, and esophagus as the saliva 
passes down into the stomach can result in enhancement of bioavailability which 
leads to a reduced dosage and improves the clinical performance and reduces 
the side effects 7, 8, 9, 12, 13, 15, 16.  
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 It is useful for some conditions that need a rapid action such as motion sickness, 
sudden episodes of allergic attack or coughing  
 
 Highly convenient for patients who are traveling anywhere, anytime and do not 
have instant access to water 7, 8, 11, 10, 12, 13. 
 
  Provide a suitable drug delivery for some drugs that have low molecular weight 
and are highly permeability13.  
 
  Due to rapid disintegration and dissolution time, orally dissolving tablets increase 
the bioavailability of insoluble and hydrophobic drugs  
 
 Improve patient safety administration by avoiding the risk of chocking or 
suffocation during oral administration due to physical obstruction 7,9,12,13,16,17.  
 
 ODTs have a unique feature by combining the advantage of solid and liquid 
dosage forms. They provide long term stability for the solid dosage form and high 
bioavailability as a liquid dosage form when placed on the mouth 7, 8, 10, 12.  
 
 Useful for pediatric, geriatric and psychiatric patients because there is no need 
for chewing 8.  
 
 Medications with a bitter taste have taken advantage of ODT technologies by the 
use of flavors and sweeteners to make them as pleasing as possible when they 
dissolve in the mouth  
 
 ODT technologies show multipurpose utilization, therefore they are suitable for 
the development of enhanced products for veterinary medicines, OTC, as well as 
prescription medicines17.  
Limitation of Mouth Dissolving Tablets 8  
 
 Insufficient mechanical strength that make ODTs difficult to handle.  
 
 Some of ODTs may leave unpleasant taste or gritty feel in the mouth if they not 
formulated properly.  
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Drug Selection Criteria 12, 19  
 
  Dose should be lower than 20 mg for FDT.  
 
  Drug should be partially nonionized at pH in oral cavity.  
 
 Drug should be diffuse and partition into the epithelium of the upper GIT (log P > 
1, or preferably >2)  
 
 Drug should have to permeate through oral mucosal tissue.  
 
Ideal Properties of MDTs20 
They should  
 Not require water to swallow and should dissolve or disintegrate in the mouth 
within a few seconds. 
 Be compatible with taste masking and other excipients. 
 Have a pleasing mouth feel. 
 Leave minimal or no residue in the mouth after oral administration. 
 Have sufficient strength to withstand the rigors of the manufacturing process and 
 Exhibit low sensitivity to environmental conditions such as humidity and 
temperature. 
Techniques of MDT Formulation 
The fast-dissolving property of the MDTs is attributed to quick ingress of water 
into tablet matrix resulting in rapid disintegration. Hence, the basic approaches to 
develop MDTs include: 
Maximizing the porous structure of the tablet matrix. 
 Incorporating the appropriate disintegrating agent/agents. 
 Using highly water-soluble excipients in the formulation. 
So far, several techniques have been developed on the basis of different 
principles. The resulting dosage forms vary on grounds like mechanical strength of the 
final product, drug and dosage form stability, mouth feel, taste, rate of dissolution and 
absorption from saliva, swallowability and overall bioavailability. 
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 Table No:1 Shows the List of Some Patented Technologies. 
 
Patented 
Technology 
Basis of 
Technology 
Technology 
developed by 
Company 
Active Ingredient 
(Brand Names) 
Zydis Lyophilization R.P.Scherer Loratidine (Claritin Reditab 
and Dimetapp Quick 
Dissolve) 
 
Quicksolv 
Lyophilization Janssen 
pharmaceutics 
Cisapride monohydrate 
(Propulsid Quicksolv), 
Risperidone (Risperdal MTab) 
 
Orasolv 
 
Direct 
Compression 
 
Cima Labs,Inc. Paracetamol (Tempra 
Quicklets), Zolmitriptan 
(Zolmig Repimelt), Hyoscyamine 
Sulfate. 
Durasolv Direct 
compression 
Cima Labs, Inc. (NuLev) Zolmitriptan 
(Zolmig ZMT) 
Flashtab Direct 
compression 
Ethypharm Ibuprofen (Nurofen 
FlashTab) 
 
Wowtab 
Direct 
compression 
Yamanouchi 
Pharma 
Tech. Inc. 
Famotidine (Gaster D) 
 
Advatab 
Microcaps and 
diffuscap CR 
Technology 
Eurand 
International 
AdvaTab cetrizine, 
AdvaTab Paracetamol 
 
Flashdose 
Cotton Candy 
Process 
Fuisz 
Technology, 
Ltd. 
Tramadol HCl 
(Relivia Flash dose) 
Oraquick Micromask 
taste masking 
KV 
Pharm.Co.,Inc. 
Hyoscyamine SulfateODT 
Ziplets Direct 
compression 
Eurand 
International 
Ibuprofen (Cibalgina 
DueFast) 
Lyoc Lyophilization Farmalyoc Phloroglucinol Hydrate 
(Spasfon Lyoc) 
 
 
Various manufacturing techniques for MDDDS include: 
1. Lyophilization 
2. Moulding 
3. Direct Compression 
4. Cotton Candy Process 
5. Spray Drying 
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6. Sublimation 
7. Mass Extrusion 
8. Nanonization 
9. Fast Dissolving Films 
 
Freeze-Drying or Lyophilization21 
In freeze-drying process, the water is sublimed from the product after it is frozen. 
This technique forms the basis of Zydis, Quicksolv and Lyoc technologies which are 
used to manufacture MDTs. Jaccard and Leyder used lyophilization to develop an oral 
formulation that not only dissolved rapidly but also exhibited improved bioavailability of 
several drugs such as spironolactone and trolendomycin. Corveleyn and Remon studied 
various formulation and process parameters by using hydrochlorothiazide as a model 
drug. 
Zydis technology (ZT) is a patented technique which had been used for drugs 
like famotidine, loperamide, piroxicam, oxazepam, lorazepam, domeperidone, 
brompheniramine, olanzepine, ondansetron and rizatriptan. Thirteen products are 
currently available in the market, which had been manufactured using this technology. 
In U.S., the MDT products available are: Claritin Reditab, Dimetapp Quick Dissolve, 
Feldene Melt, Maxalt- MLT, Pepcid RPD, Zofran ODT and Zyprexa Zydis. In the 
worldwide market, Zydis formulations are also available for oxazepam, lorazepam, 
loperamide, and  enalapril 23. 
ZT utilizes a unique freeze-drying process to manufacture finished dosage units 
which significantly differ from conventional oral systems 24. The process involves the 
following steps: 
Stage 1 - bulk preparation of an aqueous drug solution or suspension and its 
subsequent precise dosing into pre-formed blisters. It is the blister that actually forms 
the tablet shape and is, therefore, an integral component of the total product package. 
Stage 2 - passing the filled blisters through a specially designed cryogenic 
freezing process to control the ultimate size of the ice crystals which ensures that the 
tablets possess a porous matrix to facilitate the rapid disintegration property. These 
10 
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frozen units are then transferred to large-scale freeze dryers for the sublimation 
process, where the majority of the remaining moisture is removed from the tablets. 
Stage 3 - sealing the open blisters using a heat-seal process to ensure stability and 
protection of the product from varying environmental conditions. 
Lyoc is a porous and solid galenic form obtained by lyophilization of an oil-in-
water emulsion placed directly in the blister alveolus 14,25. Its unusual properties are the 
result of its unique method of preparation, which involves freezing a thickened (paste 
like) emulsion containing the active as bulk or as coated microparticles. This product is 
capable of accommodating high dose and disintegrates rapidly but possesses poor 
mechanical strength. 
Quicksolv is a porous solid form obtained by freezing an aqueous 
dispersion/solution of the drug containing matrix and then drying it by removing the 
water using excess of alcohol (solvent extraction)26. The final form disintegrates very 
rapidly but is limited to low drug content and can be used only for those drugs that are 
insoluble in the extraction solvent. The ideal drug characteristics required for this 
technology are relative low aqueous solubility, fine particle size < 50 μm 27, 28 and good 
aqueous stability in the suspension. 
The maximum drug loading capacity for water insoluble and soluble drugs are 
400 mg and 60 mg, respectively 12, 27. The primary problems associated with water 
soluble drugs are the formation of eutectic mixtures resulting in freezing-point 
depression and the formation of a glassy solid on freezing which might collapse on 
drying due to loss of supporting structure during sublimation process 12, 13, 27. 
MDTs manufactured using lyophilization process, usually contain excipients like 
polymers (e.g., gelatin, alginates and dextrin) to provide strength and rigidity to tablets; 
polysaccharides (e.g., mannitol and sorbitol) to impart crystallinity and hardness to the 
matrix and to improve palatability; collapse protectants (e.g., glycine) to prevent the 
product from shrinking in its packaging during manufacturing or storage; flocculating 
agents (e.g., xanthan gum and acacia) to provide uniform dispersion of drug particles; 
preservatives (e.g., parabens) to prevent microbial growth; permeation enhancers (e.g., 
sodium lauryl sulfate) to improve transmucosal permeability; pH adjusters (e.g. citric 
11 
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acid etc.) to optimize chemical stability; flavors and sweeteners to improve patient 
compliance and water to ensure formation of porous units. 
Advantages 
The major advantage of using this technique is that the tablets produced by this 
technology have very low disintegration time and have great mouthfeel due to fast 
melting effect. 
Disadvantages 
Although being a fairly routine process, lyophilization has some disadvantages 
like it is a relatively expensive and time consuming process. Furthermore, the product 
obtained is poorly stable and fragile, rendering conventional packaging unsuitable. 
 
Tablet Moulding 
Moulded tablets invariably contain water-soluble ingredients due to which the 
tablets dissolve completely and rapidly. Following are the different tablet moulding 
techniques: 
Compression Moulding Process 
This manufacturing process involves moistening the powder blend with a 
hydroalcoholic solvent followed by pressing into mould plates to form a wetted mass 
(compression moulding). The solvent is then removed by air drying, a process similar to 
the manufacture of tablet triturates. Such tablets are less compact than compressed 
tablets and possess a porous structure that hastens dissolution 15. 
Heat-Moulding Process 
Heat-moulding process involves setting the molten mass containing a dispersed 
drug . This process uses agar solution as a binder and a blister packaging well as a 
mould to manufacture the tablet. A suspension containing drug, agar and sugar is 
prepared followed by pouring the suspension into the blister packaging well, solidifying 
the agar solution at room temperature to form a jelly and finally drying at approximately 
30 °C under vacuum. 
Moulding by Vacuum Evaporation without Lyophilization 30 
This process involves pouring of the drug excipient mixture (in the form of a 
slurry or paste) into a mould of desired dimension, freezing the mixture to form a 
12 
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solidified matrix and finally subjecting it to vacuum drying at a temperature within the 
range of its collapse temperature and equilibrium freezing temperature. This results in 
the formation of a partially collapsed matrix. This method differs from the lyophilization 
technique, as in the former the evaporation of free unbound solvent occurs from a solid 
through the liquid phase to a gas, under controlled conditions, instead of the sublimation 
which takes place in the latter process. Unlike lyophilization, vacuum drying helps to 
densify the matrix and thereby improves the mechanical strength of the product. Pebley 
et al.  evaporated the frozen mixture containing a gum (e.g., acacia, carageenan, guar, 
tragacanth or xanthan), a carbohydrate (e.g., dextrose, lactose, maltose, mannitol or 
maltodextrin) and solvent in a tablet-shaped mould to design a MDT with a 
disintegration time of about 20 – 60 secs.  
Tablets produced by moulding are solid dispersions. The drug, depending on its 
solubility in the carrier, exists either as discrete particles or microparticles dispersed in 
the matrix and is dissolved totally/partially to form a solid solution/dispersion in the 
carrier matrix. 
Advantages 
As the dispersion matrix is made from water-soluble sugars, moulded tablets 
disintegrate more rapidly and offer improved taste. These properties are enhanced 
when tablets with porous structures are produced or when components that are 
physically modified by the moulding process are used. In comparison to lyophilization 
process, tablets produced by moulding technique are easier to adapt to the industrial 
scale. 
Disadvantage 
As the moulded tablets have poor mechanical strength, they may undergo 
erosion and breaking during handling. Though hardening can increase the strength of 
the tablets but it would be at the cost of their disintegration time. 
 
Direct Compression (DC) 
DC is the simplest and most cost effective tablet manufacturing technique for 
MDTs as they can be fabricated using conventional tablet manufacturing and packaging 
machinery and also due to availability of tableting excipients with improved flow, 
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compressibility and disintegration properties, especially tablet disintegrants, 
effervescent agents and sugar based excipients. 
Disintegrants 
In many MDT products based on DC process, the disintegrants mainly affect the 
rate of disintegration and hence dissolution which is further enhanced in the presence of 
water soluble excipients and effervescent agents. 
The introduction of superdisintegrants has increased the popularity of this 
technology 27. Tablet disintegration time can be optimized by focusing on the 
disintegrants concentration. Below a critical disintegrant concentration, tablet 
disintegration time becomes inversely proportional to disintegrant concentration. 
However, above the critical concentration level of disintegrant, disintegration time 
remains approximately constant or the decrease is insignificant 22. 
Another DC based technology; Flashtab contains coated crystals of drug and 
microgranules along with disintegrants30. In this technology, two types of disintegrants 
are used: a disintegrating agent (e.g., modified cellulose), which has a high swelling 
force and a swelling agent (e.g., starch) which has a low swelling force 30. 
Bi et al. and Watanbe used microcrystalline cellulose (MCC) and low substituted 
hydroxypropyl cellulose (HPC) to manufacture MDTs wherein the ratio of MCC to HPC 
varied from 8:2 to 9:1. Ito and Sugihara investigated the application of agar powder as a 
disintegrant due to its property of absorbing water and considerable swelling without 
forming a gel at physiological temperature. 
Effervescent Agents 
The evolution of CO2 as a disintegrating mechanism forms the basis of the 
patented Orasolv technology (OT) and is frequently used to develop over-the-counter 
formulations 26–30. The product contains microparticles and is slightly effervescent in 
nature. Saliva activates the effervescent agent which causes the tablet to disintegrate. 
The OT had been utilized in fabrication of six marketed products: four Triaminic 
Softchew formulations, Tempra FirsTabs and Remeron SolTab. 
The present technology uses the concept of effervescence to achieve fast-
disintegration. In this technology, the microparticles are prepared by dispersing the drug 
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into a suitable polymer (ethyl cellulose, methyl cellulose, acrylate or methacrylic acid 
resins) along with other excipients (mannitol and magnesium oxide).  
The drug and mannitol are added to the polymeric dispersion under stirring, 
followed by addition of magnesium oxide. Here, mannitol and magnesium oxide are 
known as release promoters as they aid in drug release from the polymeric coating. 
This mixture is then dried for one hour at 50 °C, delumped and dried for another hour at 
the same temperature.  
The material is then screened (8-mesh) and dried for one hour at 60 °C. The 
formed microparticles, effervescent agents and other excipients are blended and 
compressed into tablets at 1.0–2.0 kg hardness. The tablets obtained are fragile with in-
vivo disintegration time of less than one minute. As the tablets are very soft, they are 
packed into aluminium blisters using a specially designed packaging system.  
To reduce their friability, a novel method, known as particulate effervescent 
couple, had been developed. In this method the organic acid crystals are coated using a 
stoichiometrically low quantity of base material as compared to acid. The particle size of 
the organic acid crystals is carefully chosen to be greater than the base material so that 
base gets uniformly coated onto the acid crystals. 
The coating process is initiated by the addition of a reaction initiator, which in this 
case, is purified water. The reaction is allowed to proceed only to an extent of 
completion of base coating on organic acid crystals. The required end-point for the 
reaction termination is determined by measuring CO2 evolution. The resulting 
effervescent couple can be used in tablet preparation by mixing with polymer-coated 
drug particles and other required excipients 31.  
Though, the Orasolv tablet has the appearance of a traditional compressed 
tablet, they are lightly compressed and are weaker and more brittle than the 
conventional tablets. Therefore, a special handling and packaging system for Orasolv 
was developed 30. An advantage of low degree of compaction is that the particle coating 
used for taste masking is not compromised by fracture during compression. 
Durasolv, a second-generation technology was developed to produce robust 
MDTs. Durasolv has much higher mechanical strength than its predecessor due to use 
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of higher compaction pressure during compression. It is thus produced in a much faster 
and cost effective manner and can be packed in either traditional blister packs or vials. 
The limitations of Durasolv is its low drug loading capacity and high compaction 
pressure which are not suitable for incorporation of taste masked coated pellets. 
Therefore, the Durasolv technology is best suited for relatively small doses of drug .  
This technology has been applied in the fabrication of two products: NuLev and 
Zomig ZMT. However, the major drawback of effervescent excipients is their 
hygroscopicity which require control of humidity during processing and protection of the 
final product resulting in increase in the cost of the product. 
Sugar-Based Excipients 
Another approach to manufacture MDTs by DC is the use of sugar-based 
excipients (e.g., dextrose, fructose, isomalt, lactitol, maltitol, maltose, mannitol, sorbitol, 
starch hydrolysate, polydextrose and xylitol) which display high aqueous solubility and 
sweetness and hence, imparts taste masking and a pleasing mouth feel. 
Mizumoto et al., have classified sugar-based excipients into two types based on 
their mouldability and dissolution rate. 
Type I saccharides (e.g., lactose and mannitol) exhibit low mouldability but high 
dissolution rate. 
Type II saccharides (e.g., maltose and maltitol) exhibit high mouldability but low 
dissolution rate. 
Mouldability is defined as the capacity of the compound to be compressed/ 
moulded and to dissolve. It does not refer to the formation of a true mould by melting or 
solvent wetting process. The mouldability of Type I saccharide can be improved by 
granulating it with a Type II saccharide solution. 
The above technology forms the basis of WOWTAB which involves the use of 
fluidized bed granulation for the surface treatment of Type I saccharide with Type II 
saccharide. This technique has been used in the production of Benadryl Fast melt 
tablets. Here, two different types of saccharides are combined to obtain a tablet 
formulation with adequate hardness and fast dissolution rate. Due to its significant 
hardness, the WOWTAB formulation is more stable to the environmental conditions 
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than the Zydis or Orasolv and is suitable for both conventional bottle and blister 
packaging.  
The taste masking technology utilized in the WOWTAB is proprietary and claims 
to offer superior mouthfeel due to the patented smooth-melt action 26. 
In the process of granulation, low mouldable sugar was coated with high 
mouldable sugar followed by a specific humidity treatment, to achieve fast 
disintegration. The resulting tablet had a hardness of 1.0–2.0 kg (tablet-size dependent) 
and presented a preferable disintegration time of 1–40 secs. Various classes of drugs 
can be incorporated into the above sugar combination to achieve a MDT with optimum 
performance characteristics. A preferable ratio of 5–10% w/w of high mouldable sugar 
was found to be sufficient to achieve the desired hardness and disintegration property 
25. 
A series of experiments had been conducted to develop a MDT using a 
combination of starch/cellulose and one or more water-soluble saccharides27. Erythritol 
was found to be the best saccharide because it displayed rapid disintegration, good 
tolerability, sweetening and a refreshing mouth feel due to its negative heat of solution. 
Recently, the Ziplet technology was developed, which can be used for water 
insoluble drugs or drugs as coated microparticles. It was found that the addition of a 
suitable amount of a water-insoluble inorganic excipient combined with one or more 
effective disintegrants imparted an excellent physical resistance to the MDT and 
simultaneously maintained optimal disintegration even at low compression force and 
tablet hardness.  
In fact, breakage of the tablet edges or formation of powder during manufacturing 
and opening of the blister pack is avoided because of its superior mechanical 
resistance. The use of water-insoluble inorganic excipients also offers better 
enhancement of disintegration characteristics in comparison to the most commonly 
used water-soluble sugars or salts. In fact, tablets composed primarily of water-soluble 
components often tend to dissolve rather than disintegrate, resulting in much longer 
disintegration time. As the soluble components dissolve on the tablet’s outer layer, a 
concentrated viscous solution is formed, which reduces the rate of water diffusion into 
the tablet core. 
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Cotton Candy Process 
The FLASHDOSE® is a MDDDS manufactured using Shearform™ technology in 
association with Ceform TI™ technology to eliminate the bitter taste of the medicament. 
The Shearform technology is employed in the preparation of a matrix known as ‘floss’, 
made from a combination of excipients, either alone or with drugs.  
The floss is a fibrous material similar to cotton-candy fibers, commonly made of 
saccharides such as sucrose, dextrose, lactose and fructose at temperatures ranging 
between 180–266 °F. 
However, other polysaccharides such as polymaltodextrins and polydextrose can 
be transformed into fibers at 30–40% lower temperature than sucrose. This modification 
permits the safe incorporation of thermolabile drugs into the formulation.  
The tablets manufactured by this process are highly porous in nature and offer 
very pleasant mouthfeel due to fast solubilization of sugars in presence of saliva. The 
manufacturing process can be divided into four steps as detailed below. 
I. Floss Blend 
In this step, 80% sucrose in combination with mannitol/dextrose and 1% 
surfactant is blended to form the floss mix. The surfactant acts as a crystallization 
enhancer in maintaining the structural integrity of the floss fibers. It also helps in the 
conversion of amorphous sugar into crystalline form from an outer portion of amorphous 
sugar mass and subsequently converting the remaining portion of the mass to complete 
crystalline structure. This process helps to retain the dispersed drug in the matrix, 
thereby minimizing migration out of the mixture 29. 
II. Floss Processing 
The floss formation machine uses flash heat and flash flow processes to produce 
matrix from the carrier material. The machine is similar to that used in ‘cotton-candy’ 
formation which consists of a spinning head and heating elements.  
In the flash heat process, the heat induces an internal flow condition of the carrier 
material. This is followed by its exit through the spinning head (2000–3600 rpm) that 
flings the floss under centrifugal force and draws into long and thin floss fibers, which 
are usually amorphous in nature 30. 
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III. Floss Chopping and Conditioning 
This step involves the conversion of fibers into smaller particles in a high shear 
mixer granulator. The conditioning is performed by partial crystallization through an 
ethanol treatment (1%) which is sprayed onto the floss and subsequently evaporated to 
impart improved flow and cohesive properties to the floss . 
IV. Blending and Compression 
Finally, the chopped and conditioned floss fibers are blended with the drug along 
with other required excipients and compressed into tablets. In order to improve the 
mechanical strength of the tablets, a curing step is also carried out which involves the 
exposure of the dosage forms to elevated temperature and humidity conditions, (40 °C 
and 85% RH for 15 min). This is expected to cause crystallization of the floss material 
that results in binding and bridging to improve the structural strength of the dosage 
form. 
Spray-Drying 
Allen et al.,have used spray-drying for the production of MDTs. The formulations 
contained hydrolyzed and unhydrolyzed gelatin as a supporting agent for the matrix, 
mannitol as a bulking agent and sodium starch glycolate/croscaramellose as a 
disintegrant.  
Disintegration and dissolution were further enhanced by adding an acid (e.g., 
citric acid) or an alkali (e.g., sodium bicarbonate). The suspension of above excipients 
was spray-dried to yield a porous powder which was compressed into tablets. Tablets 
manufactured by this method disintegrated in < 20 secs in an aqueous medium. 
 
Sublimation 
Sublimation has been used to produce MDTs with high porosity. A porous matrix 
is formed by compressing the volatile ingredients along with other excipients into 
tablets, which are finally subjected to a process of sublimation.  
Inert solid ingredients with high volatility (e.g., ammonium bicarbonate, 
ammonium carbonate, benzoic acid, camphor, hexamethylene tetramine, naphthalene, 
phthalic anhydride, urea and urethene) have been used for this purpose.  
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Solvents such as cyclohexane and benzene were also suggested for generating 
the porosity in the matrix. Makino et al., reported a method using water as a pore-
forming material. 
Mass-Extrusion 
This technology involves softening of the active blend using the solvent mixture 
of water soluble polyethylene glycol and methanol and expulsion of softened mass 
through the extruder or syringe to get a cylindrical shaped extrude which are finally cut 
into even segments using heated blade to form tablets. This process can also be used 
to coat granules of bitter drugs to mask their taste 25. 
Nanonization 
A recently developed Nanomelt technology involves reduction in the particle size 
of drug to nanosize by milling the drug using a proprietary wet-milling technique .  
The nanocrystals of the drug are stabilized against agglomeration by surface 
adsorption on selected stabilizers, which are then incorporated into MDTs. This 
technique is especially advantageous for poorly water soluble drugs.  
Other advantages of this technology include fast disintegration/dissolution of 
nanoparticles leading to increased absorption and hence higher bioavailability and 
reduction in dose, cost effective manufacturing process, conventional packaging due to 
exceptional durability and wide range of doses (up to 200 mg of drug per unit). 
Fast Dissolving Films 
It is a new frontier in MDDDS that provides a very convenient means of taking 
medications and supplements. In this technique, a non-aqueous solution is prepared 
containing water soluble film forming polymer (pullulan, carboxy methylcellulose, 
hydroxypropyl methylcellulose, hydroxyl ethylcellulose, hydroxyl propylcellulose, 
polyvinyl pyrrolidone, polyvinyl alcohol or sodium alginate, etc.), drug and other taste 
masking ingredients, which is allowed to form a film after evaporation of solvent. In case 
of a bitter drug, resin adsorbate or coated microparticles of the drug can be incorporated 
into the film. 
 This film, when placed in mouth, melts or dissolves rapidly, releasing the drug in 
solution or suspension form. The features of this system include paper thin films of size 
less than 2X2 inches, dissolution in 5 sec, instant drug delivery and flavored after taste.  
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 MDTs with Patented Taste Masking Technology 
There are number of patented taste masking technologies which had been 
utilized to manufacture MDTs with acceptable taste. CIMA Labs’ taste masking 
technique involving coating of drug with dissolution retarding excipient, Microcaps 
process involving microencapsulation by coacervation-phase seperation technique ,  
Solutab technology involving coating of drug with sustained release agent 
followed by coating with enteric polymer and finally with mannitol [68] and blending of 
drug with cyclodextrins are some of the taste masking approaches applied in fabrication 
of MDTs.  
One more formulation in this category is OraQuick formulation which produces 
microspheres, known as MicroMask, which has superior mouthfeel over other taste-
masking alternatives. This process does not involve the use of solvents and therefore, 
leads to faster and more efficient production.  
Moreover, relatively lower heat of production makes OraQuick appropriate for 
heat-sensitive drugs. The matrix that protects the drug in microencapsulated particles is 
more pliable which enables the tablets to be compressed with significant mechanical 
strength without disrupting the taste-masking property.  
Alongwith good taste-masking ability, OraQuick also claims quick dissolution (in 
secs) of the MDT. This technology had also been utilized in the development of MDTs 
containing Hyoscyamine sulfate, which is a bitter tasting anticholinergic/antispasmodic 
drug. 
 AdvaTab technology utilizes a combination of Microcaps technology for taste 
masking and Diffuscap controlled release technology for the development of a highly 
differentiated controlled release MDT product 31. 
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2. REVIEW OF LITERATURE 
 
1. Neena Bedi et.al, developed Formulation and Evaluation of Mouth Dissolving Tablets 
of OxcarbazepineTablets produced by direct compression method contain crospovidone 
as a superdisintegrant and aspartame as a sweetener. Solid dispersions of 
oxcarbazepine with polyvinylpyrrolidone K-30 and polyethylene glycol 6000 in different 
weight ratios were prepared with a view to increase its water solubility32.  
2. B. P. Patel et.al, developed Formulation and Evaluation of Mouth Dissolving Tablets 
of Cinnarizine by effervescent, superdisintegrant addition and sublimation methods. All 
the three formulations were evaluated for disintegration time, hardness and friability, 
among these superdisintegrant addition method showed lowest disintegration time; 
hence it was selected for further studies. Further nine batches (B1-B9) were prepared 
by using crospovidone, croscarmellose sodium and L-HPC in different concentrations 
such as 5, 7.5 and 10%. All the formulations were evaluated for weight variation, 
hardness, friability, drug content, in vitro disintegration time, wetting time, in 
vitro dissolution. Formulation with 10% L-HPC showed the less disintegration time (25.3 
s) and less wetting time (29.1 s). In vitro dissolution studies showed total drug release at 
the end of 6 min. 
Keywords: Cinnarizine, In vitro disintegration time, mouth dissolving tablets, 
sublimation, wetting time33.  
3. Sharma V et.al, developed mouth dissolving tablet that disintegrates rapidly in mouth 
by using tasteless complex of Levocetirizine and Tulsion-335. Effect of different 
parameters such as swelling time, resin activation, drug resin ratio as well as stirring 
time was optimized by taste and percentage drug loading. Formulated DRC (Drug Resin 
Complex) was characterized by infrared spectroscopy, thermal analysis and X-ray 
diffraction pattern. Tablets were formulated by wet granulation with PVP as binder, 
Sodium Starch Glycolate (SSG) and Crospovidone as super disintegrants. In these 
batches optimum hardness was achieved but disintegration time was found to be very 
high as ≥ 70 second, so further trials were planned by using different superdisintegrants 
such as Croscarmellose sodium, Sodium Starch Glycolate (SSG) as well as 
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Crospovidone by wet granulation method. Tablets formulated with 7.5% crospovidone 
showed comparatively low disintegration time (25 sec), wetting time (20 sec) and 
friability (0.60 %) than the other batches. In present study we optimized the conditions 
required for maximum drug loading of Levocetirizine with Tulsion-335. Among different 
superdisintergants, crospovidone was found suitable with drug-resin complex to get the 
low disintegration time, wetting time and friability of tablets. 
Keywords: Drug-resin complex; Levocetirizine; Superdisintegrant; Tulsion-33534 
 
4. Goel H et.al, studied a variety of dosage forms like tablets, films, wafers, chewing 
gums, microparticles, nanoparticles etc. have been developed for enhancing the 
performance attributes in the orally disintegrating systems. Advancements in the 
technology arena for manufacturing these systems include the use of freeze drying, 
cotton candy, melt extrusion, sublimation, direct compression besides the classical wet 
granulation processes. Taste masking of active ingredients becomes essential in these 
systems because the drug is entirely released in the mouth. Fluid bed coating, 
agglomeration, pelletization and infusion methods have proven useful for this purpose. It 
is important to note that although, freeze dried and effervescent disintegrating systems 
rapidly disintegrate in contact with fluids, they do not generally exhibit the required 
mechanical strength. Similarly, the candy process cannot be used for thermolabile 
drugs. In the light of the paradoxical nature of the attributes desired in orally 
disintegrating systems (high mechanical strength and rapid disintegration), it becomes 
essential to study the innovations in this field and understand the intricacies of the 
different processes used for manufacturing these systems. This article attempts at 
discussing the patents relating to orally disintegrating systems with respect to the use of 
different formulation ingredients and technologies35. 
 
5. Chachin M et.al,studied pharmacological  effect of Telmisartan (Micardis) is a potent, 
long-lasting, nonpeptide angiotensin II type-1 (AT(1)) receptor blocker (ARB) that is 
indicated for the treatment of essential hypertension. In receptor binding studies, 
telmisartan showed a high affinity and selectivity for the human AT(1) receptors 
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compared with AT(2) receptors and a slower dissociation rate from the human AT(1) 
receptor than those of ARBs. In isolated aorta rings, telmisartan was shown to be an 
insurmountable antagonist of AII-induced contractions. The inhibitory effects of 
telmisartan on AII-induced contraction persisted even after wash-out procedures. In 
animal models such as spontaneous hypertension rats and renovascular hypertensive 
rats, telmisartan produced the consistent reduction of blood pressure. Furthermore, 
there were no rebound phenomenon and no tolerance to the drug developed in the 
repeated oral administration. Telmisartan has a longer terminal elimination half-life 
(about 24 h) than the other ARBs. In patients with mild-moderate hypertension, 
trough/peak ratios for telmisartan were above 80%. In Japanese patients with mild-
moderate hypertension, telmisartan produced a significant reduction in blood pressure 
(effective rate: 76.0%) with a good safety profile. Therefore, telmisartan is expected to 
be effective in the treatment of hypertension, producing sustained 24-h blood pressure 
control36. 
 
6.Chaudhari PD et. al, Studied the bitter taste of famotidine was masked using 
Eudragit in different ratio. The different superdisintegrants like Ac-di-sol and 
polyplasdone with their varying concentration used for disintegration of tablet in mouth.  
After dissolution study he concluded that all formulation showed faster release rate 
than marketed formulation37   .  
 
7.Takao M et. al.,  Tried to developed novel fast-disintegration tablet as a user   
friendly  dosage  form  for  the  aged.  Used mannitol,  lactose,  glucose, magnesium  
stearate  as  excipient.  Prepared  many  formulations  using  different exicipients in  
different  formulation,  various  parameters  checked  and  compare. They  concluded 
that tablet contain mannitol, glucose and lactose showed quick disintegration time, 
but very low hardness and tablet contain maltose and mannitol having high  hardness 
but slow disintegration time38. 
 
8.Zhao N et. al.,  Compared disintegration efficiency and to developed a discriminating 
model for 3 classes of superdisintegrants represented of AC-Di- Sol,  primoses and 
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polyplasdone X L 10. The study were thus provides a closer look at the  functionality 
of superdisintegrants in promoting tablet disintegration and  development  of  model  
formulation  with  examinated  by  videography  and dissolution  profile.  AC-Di-Sol 
was  found  to  disintegrate  tablet  rapidly  into apparently  primary  particles.  3 
disintegrants  representing  each of the 3  main classes of superdisintegrants differed 
in their ability to disintegrate model tablets into their primary particles39. 
 
9.Desai   SA   et.   al.,    prepared o r  d i s s o l v i n g    tablets   of   promethazine 
hydrochloride were prepared by using superdisintegrant sodm starch glycolate and 
cross carmellose sodium by direct compression method. The prepared tablets were 
evaluated for uniformity of weight, tensile strength, content uniformity, hardness, 
friability, wetting time, invitro and invivo dispersion time and invitro drug release40. 
 
10.Nandgude TD et. al.,  Prepared diphenhydramine tannate fast dissolving tablet   by  
wet  granulation  method  after  incorporating  superdisintegrants  like sodium  
glycolate  and  crospovidone  in  different  concentration.  The  tablets  are subjected to 
evaluation with post compressional parameters like weight variation, hardness and 
friability, tensile strength, water absorption ratio, in-vitro dispersion time,  in  vivo  
dispersion  time.  Concluded that conventional tablet show 100% release after 7 hrs 
where as mouth disintegration tablet achieved maximum release 3-4 hrs. Tablet 
containing SSG show superior organoleptic properties along with excellent in-vitro 
dispersion time41. 
 
11.Uddhav  S  et.  al.,   Described  manufacturing  technologies  for  mouth dissolving 
tablets showing that incorporation of  an existing medicine into a new drug  delivery  
system  can  significantly  improve  its  performance  in  terms  of efficacy,  safety  
and  improved  patient  compliance.  In these studies they had described different 
types of technologies employed for the formulation of mouth dissolving tablets i.e. 
freeze drying, spray drying, sublimation and comparison of sugar based excipients 
with their dissolution rate and compressibility42. 
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12.Shishu et. al., Prepared taste masked  granules using aminoalkyl methacryl 
atecopolymer  by the extrusion method  and   formula rapidly disintegrating tablet by 
direct compression method.  The tablet prepared by using microcrystalline  cellulose  
and  sodium  starch  glycolate  ate  as  disintegrant. Concluded that tablet had a 
good taste and rapidly disintegrated in the mouth were useful and practical for pediatric 
and geriatric population43. 
 
13.Sharma  S  et.  al.,  Formulated  promethazine  theoclate  solid  dispersion with 
PEG 4000 by using optimized amount of superdisintegrant.A phase solubility method 
was  used  to  evaluate the effect  of  various water-soluble polymers on aqueous 
solubility  of  promethazine theoclate.PEG 4000 was selected  and solid dispersion 
were prepared by method of  fusing44 Chaudhari  PD et.  al., Formulated and 
evaluated taste masked orodispersible dosage form of levocetirizine. An attempt was 
made to mask the taste, by complexation technique using ion-exchange resin, tulsion 
335 formulate in to a orodispersible dosage form. The drug loading onto ion exchange 
resin was optimized for concentration of resin, swelling time of resin, stirring time, pH 
of resin solution, stirring temperature.  Shows bitter drug successfully taste masked 
using suitable ion exchange resin. The drug resin complex orodispersible tablets 
were formulated and the evaluated for drug content, content uniformity, weight 
variation, hardness, friability, water absorption ratio, in-vitro and in-vivo drug 
release45. 
 
14.Raghu NB ET. al., Studied on taste masking of drotaverine hydrochloride by the 
complexation technique. The drug loading process was optimized for taste masking 
and drug: resin ratio, the resinate was evaluated for bulk density, tap density, taste 
and characterization was  done  us ing DSC.  The tas te  masked drotaverine 
complex was incorporated into palatable melt in mouth tablet and evaluated various 
quality control parameters.  The mouth dissolve tablets had optimum physiochemical 
property with complete release of drug with 30 min46. 
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15.Swamy PV et. al., Developed or dispersible tablet of meloxicam using different 
superdisintegrants.  Combinations of  sodium starch  glycolate- croscarmellose sodium 
or sodium starch glycolate–crospovidone were used along with   directly   compressible  
mannitol. The  prepared   batches  evaluated  for hardness, friability, wetting time, 
water absorption ratio like various parameters. He concluded that the formulation 
prepared using 2% w/v sodium starch glycolate and  15%  croscarmellose  sodium  
was  found  better  formulation  compare  to conventional tablet47. 
 
16.He X et.al.,Developed the rapidly dispersing tablet of a poorly wettable compound–
formulation  DOE  and  mechanistic  study  of  effect  of  formulation excipient on 
wetting of celecoxib. In this work a tablet was placed in water and the turbidity of the 
resulting “dynamic” suspension was measured. They describe the novel method to 
enhance the dissolution rate for poorly soluble compounds by reduction   in particle 
size, with screening formulation statistical   design o f  experiments,   mechanistic   
studies,   optimization   design   of   experiments   and analytical methods like turbidity 
test, contact angle analysis, microscopic test48. 
 
17.Adamo F et. al., Developed eight formulations containing Ibuprofen  in the form of 
orally disintegrating tablets.  To prevent bitterness of drug he masked the taste of  
drug using taste masking agents.   Aspartame used as a sweeter in formulation,   
mannitol used  as a binder and  explotab  were added  as superdisintegrant  and  
compacted  under  low  compression  force. Dissolution profile suggest that the 
combined action of hydrophobic lecithin and coating delay the release of the drug from 
tablets with respect to when it is free or in the form of simple granules49. 
 
18.Setty CM et. al.,Developed fast dispersible  Aceclofenac  tablets and study  the 
effect of superdisintegrants on wetting time, disintegration time, drug content,   in-
vitro   release   and   stability   parameter   using   direct   compression technique.  The  
parameters  were  tested  for  significance  by  using  analysis  of variance  
(ANOVA:Single  factor).  The stability study  showed  that  tablet containing 
superdisintegrants were sensitive to high humidity condition.  He also concluded that 
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although functional differences existed between the superdisintegrants, the fast 
dispersible aceclofenac tablets could be prepared by using any of the 
superdisintegrants used50. 
 
19.Mulla JA et. al., Prepared  promethazine hydrochloride mouth disintegrating tablet  
that have been  used for  prevention of emesis and nausea using  disintegrants like 
Ac-di-sol, explotab, polyplasdone and MCC along with other  additives  by  directly  
compression techniques. It was observed that the concentration of the 
superdisintegrants had an effect on disintegration time and in-vitro dissolution time and 
in-vitro dissolution characteristics.  Ac-di-sol was found to be better as compared to 
other superdisintegrants used in study51. 
 
20.Rampure  MV et. al., Prepared rapidly disintegrating tablet at Alfuzosin by 
effervescent method using sodium bicarbonate and citric acid. Crospovidone, sodium 
starch glycolate and croscarmellose sodium used as superdisintegrants. The 
prepared tablet evaluated for  different  parameters  and  compare  market product.He 
showed that  the formulation containing crospovidone along  with mixture at 24% 
w/w of sodium bicarbonate and 18% w/w citric acid as overa ll best formulation52. 
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3. AIM & OBJECTIVE 
3.1 AIM:  
 
 Formulation Development and Evaluation of Fast Dissolving Tablets of Diltiazem 
Hydrochloride by Direct Compression method. 
3.2. Objectives: 
In the present work, fast dissolving tablets of Diltiazem Hydrochloride are 
planned to prepare with an intention to improve   disintegration,   dissolution   rate   and 
bioavailability of drug by using some Superdisintegrants.  
The fast dissolving tablet will be prepared by direct compression method  are  
evaluated for  various  quality  control  tests  for  tablets such as  hardness,  friability, 
weight variation, drug  content  uniformity, disintegration and dissolution. 
Fast dissolving tablets will also help in ease of administration because fast 
dissolving tablets give uniform dispersion product. 
 
3.3    Justification: 
Diltiazem is well absorbed from the gastrointestinal tract, and is subject to an 
extensive first-pass effect. When given as an immediate release oral formulation, the 
absolute bioavailability (compared to intravenous administration) of Diltiazem is 
approximately 40%. 
 Diltiazem undergoes extensive hepatic metabolism in which 2% to 4% of the 
unchanged drug appears in the urine.  
Fast dissolving tablets are formulated with an objective of improving 
disintegration and dissolution rate of the drug. Fast dissolving tablets are planned to 
prepare by using some super disintegrants. Super disintegrants are excipients used 
to promote rapid breakdown of oral solid dosage form to aid dissolution in vivo. 
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  4. PLAN OF WORK 
       
Preformulation Studies: 
 Determination of Melting Point 
 Determination of Solubility 
 To Perform Drug -Excipients Compatibility 
 To Perform Calibration By U.V 
 To Perform Pre-Compression Studies. 
 
Formulation studies: 
 To formulate optimized formula 
 Formulation of tablets by direct compression 
 
Evaluation studies: 
 Weight Variation 
 Hardness 
 Friability 
 Percentage Porosity 
 Drug Content Estimation 
 Dispersion Time 
 In-vitro Dissolution Studies 
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5. DRUG PROFILE 
DILTIAZEM HYDROCHLORIDE53 
Chemical Name: 
Chemically, Diltiazem hydrochloride is 1,5-Benzothiazepin-4(5H)one,3-(acetyl  
oxy)-5-[2- dimethylamino)ethyl] -2,3-dihydro-2-(4-methoxy phenyl) mono 
hydrochloride. 
Molecular Formula: C22H26N2O4S.HCl  
Molecular Weight: 450.99. 
Structural Formula: 
 
Description: 
 Diltiazem hydrochloride is a white to off-white crystalline powder 
with a bitter taste. It is soluble in water, methanol and chloroform.  
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Diltiazem Hydrochloride - Clinical Pharmacology: 
The therapeutic benefits of Diltiazem hydrochloride are believed to be related 
to its ability to inhibit the influx of calcium ions during membrane depolarization of 
cardiac and vascular smooth muscles. 
Mechanism of Action:- 
Hypertension 
Diltiazem HCl produces its antihypertensive effect primarily by relaxation of 
vascular smooth muscle with a resultant decrease in peripheral vascular resistance. 
The magnitude of blood pressure reduction is related to the degree of hypertension; 
thus hypertensive individuals experience an antihypertensive effect, whereas there 
is only a modest fall in blood pressure in normotensives. 
Angina 
Diltiazem HCl has been shown to produce increases in exercise tolerance, 
probably due to its ability to reduce myocardial oxygen demand. This is 
accomplished via reductions in heart rate and systemic blood pressure at 
submaximal and maximal workloads. 
Diltiazem has been shown to be a potent dilator of coronary arteries, both 
epicardial and subendocardial. Spontaneous and ergonovine-induced coronary 
artery spasms are inhibited by Diltiazem. 
Hemodynamic and Electrophysiologic Effects 
Like other calcium antagonists, Diltiazem decreases sinoatrial and 
atrioventricular conduction in isolated tissues and has a negative inotropic effect in 
isolated preparations. In the intact animal, prolongation of the AH interval can be 
seen at higher doses. 
 
 
32 
 Department of Pharmaceutics, E.G.S.Pillay College of Pharmacy, Nagapattinam. 
Pharmacokinetics and Metabolism:- 
Diltiazem is well absorbed from the gastrointestinal tract, and is subject to an 
extensive first-pass effect. When given as an immediate release oral formulation, 
the absolute bioavailability (compared to intravenous administration) of Diltiazem is 
approximately 40%. 
 Diltiazem undergoes extensive hepatic metabolism in which 2% to 4% of the 
unchanged drug appears in the urine.  
The plasma elimination half-life of Diltiazem is approximately 3.0 to 4.5 hours. 
Desacetyl Diltiazem, the major metabolite of Diltiazem, which is also present in the 
plasma at concentrations of 10% to 20% of the parent drug, is approximately 25% to 
50% as potent a coronary vasodilator as Diltiazem.  
Therapeutic blood levels of Diltiazem hydrochloride appear to be in the range 
of 40 to 200 ng/mL. There is a departure from linearity when dose strengths are 
increased; the half-life is slightly increased with dose. 
Indications and Usage for Diltiazem: 
Diltiazem Hydrochloride are indicated for the treatment of hypertension. 
Diltiazem hydrochloride may be used alone or in combination with other 
antihypertensive medications, such as diuretics. 
Contraindications: 
Diltiazem hydrochloride is contraindicated in:  
 Patients with sick sinus syndrome except in the presence of a functioning 
ventricular pacemaker; 
 Patients with second or third degree av block except in the presence of a 
functioning ventricular pacemaker;  
 Patients with hypotension (less than 90 mmhg systolic);  
 Patients who have demonstrated hypersensitivity to the drug; and  
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 Patients with acute myocardial infarction and pulmonary congestion as 
documented by X-ray on admission. 
Drug Interactions: 
Due to the potential for additive effects, caution and careful titration are 
warranted in patients receiving Diltiazem hydrochloride concomitantly with any 
agents known to affect cardiac contractility and/or conduction. Pharmacologic 
studies indicate that there may be additive effects in prolonging AV conduction when 
using beta-blockers or digitalis concomitantly with Diltiazem hydrochloride. As with 
all drugs, care should be exercised when treating patients with multiple medications.  
Diltiazem hydrochloride undergoes biotransformation by cytochrome P-450 
mixed function oxidase. Co-administration of Diltiazem hydrochloride with other 
agents which follow the same route of biotransformation may result in the 
competitive inhibition of metabolism.  
Especially in patients with renal and/or hepatic impairment, dosages of 
similarly metabolized drugs, particularly those of low therapeutic ratio such as 
cyclosporine, may require adjustment when starting or stopping concomitantly 
administered Diltiazem hydrochloride to maintain optimum therapeutic blood levels.  
Concomitant administration of Diltiazem with carbamazepine has been 
reported to result in elevated plasma levels of carbamazepine, resulting in toxicity in 
some cases. 
Diltiazem Hydrochloride Dosage and Administration: 
Administration:- 
Administer by direct IV injection, continuous IV infusion, or orally. 
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Oral Administration 
Conventional Tablets 
Administer tablets orally 3–4 times daily before meals and at bedtime. 
Extended-release Capsules 
Administer orally; directions for administration (e.g., frequency, whether to 
administer with or without food, potential for opening capsules and mixing with food) 
may vary by manufacturer and formulation; consult specific manufacturer’s 
information for additional information. 
Extended-release Tablets 
Administer orally once daily without regard to meals. Tablet should be 
swallowed whole and not chewed or crushed. 
Dosage:- 
Available as diltiazem hydrochloride; dosage expressed in terms of the salt. 
Warnings/Precautions: 
Warnings:- 
Cardiac Conduction 
Potential for abnormally slow heart rate (particularly in patients with sick sinus 
syndrome) or second- or third-degree AV block. 
Additive effects on cardiac conduction (e.g., prolonging AV node conduction) 
possible with concomitant use of diltiazem with β-adrenergic blocking agents or 
digoxin. 
If high-degree AV block occurs in patients with sinus rhythm receiving IV 
diltiazem, discontinue the drug and institute appropriate supportive measures. 
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Heart Failure 
Risk of heart failure, especially in those with preexisting ventricular 
impairment; limited experience in patients with impaired ventricular function 
receiving concomitant β-adrenergic blocking agents. Use with caution. 
Hypotension 
Possible symptomatic hypotension. 
 
 
5.1. EXCIPIENT PROFILES
54,55,56
 
 
5.1.1 CROSPOVIDONE: 
  
Nonproprietary names:  
BP: Crospovidone    
PhEur: Crospovidonum 
USPNF: Crospovidone 
Synonyms: Cross-linked povidone, polyvinyl pyrrolidone, PVPP,  
Chemical name: 1-Ethenyl-2-pyrrolidinone homopolymer 
 
Structural formula:           
     
 
 
 
Functional category: Superdisintegrant. 
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Description: Crospovidone is   a w h i t e    to   creamy- white, 
 
Applications: Crospovidone is a water-insoluble tablet disintegrant and dissolution 
agent used at 2–5% concentration in tablets prepared by direct-compression or 
wet- and dry-granulation    methods.   I t  rapidly   exhibits   high capillary   activity   
and pronounced hydration capacity, with little tendency to form gels. Studies 
suggest that t h e  p a r t i c l e  s i ze  o f    crospovidone s t r o n g l y  i n f l u e n c e s  
d i s i n t e g r a t i o n  o f  analgesic tablets.  Larger particles provide a faster 
disintegration than smaller particles.  Crospovidone can also be used as a 
solubility enhancer. 
 
 
 
 
5.1.2 CROSCARMELLOSE SODIUM (CCS): 
 
Nonproprietary Name: USPNF: Croscarmellose sodium. 
 
Synonyms: Ac-Di-sol; cross-linked  carboxy methylcellulose Sodium; Primellose 
 
Functional category: Tablet and capsule disintegrants 
 
Chemical name: Cellulose, carboxymethyl   ether,   sodium salt. 
 
Structural formula: 
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Description: Croscarmellose sodium occurs as a n odorless, white-colored powder. 
 
Molecular weight: 90000-700000. 
 
pH (1% w/v dispersion) : 5.0-7.0. 
 
Application: Crospovidone is a water-insoluble tablet disintegrant and dissolution 
agent used at 2–5% concentration in tablets prepared by direct-compression or 
wet and dry granulation    methods. 
 
 
 
 
5.1.3 SODIUM STARCH GLYCOLATE: 
 
Synonyms: Explotab, Primogel. 
 
Nonproprietary Name: 
BP: Sodium starch glycolate 
USPNF: Sodium starch glycolate 
Functional category: Tablet and capsule disintegrant.  
 
Chemical name: Sodium carboxymethyl starch. 
 
Description: Sodium starch glycolate is a white to off- white,   odorless,   
tasteless,   free   flowing powder.  It consists of oval or spherical granules, 30-100 
μm in diameter with some less spherical granules ranging from 10-35μm in 
diameter. 
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Structural formula: 
 
 
 
Solubility: Practically insoluble in water; sparingly soluble in ethanol (95%). In water 
it swells up to 300 times its volume 
 
Stability and storage condition: It is a stable material. It should be stored in a 
well  closed  container  to  protect  from  wide variations  in  humidity and 
temperature  that may cause cracking 
 
Applications: Sodium starch glycolate is widely used in oral   pharmaceuticals   as 
a disintegrant in capsule and tablet formulations. It is commonly used in tablets 
prepared by either direct-compression or wet-granulation processes. The usual 
concentration employed in a formulation is between 2% and 8%, with the optimum 
concentration about 4%, although in many cases 2% is sufficient. Disintegration 
occurs by rapid uptake of water followed by rapid and enormous   swelling. 
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5.1.4 MICROCRYSTALLINE CELLULOSE: 
 
Nonproprietary name:  
NF   : Microcrystalline cellulose. 
USP: Microcrystalline cellulose. 
Functional category: Tablet and capsule  diluents, tablet disintegrant, suspending   
and /or   viscosity increasing agent. 
Synonyms: Cellulose gel: Crystalline cellulose: Avicel 
Empirical formula: (C6H10O5)n n=220 
Molecular weight: 36,000(approx) 
Description: Purified, partially depolymerized cellulose occurs as  a white, odorless, 
tasteless, crystalline powder composed of porous particles. 
 
Structural Formula: 
 
 
Microcrystalline cellulose 
 
Density: Apparent density - 0.28g/cm3 
 
Tap density - 0.43g/cm3 
 
Solubility: Insoluble in  water, d i l u te  acids and  most  organic solvents, slightly 
soluble in 5% w/v NaOH solution. 
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Incompatibilities: None cited in the literature. 
 
Safety: Generally regarded as safe 
 
Applications: Tablet binder/diluents (wet or dry granulation) 
 
 
 
 
 
5.1.5 LACTOSE: 
 
Synonyms: Fast-Flo, Microlose, milk sugar, Pharmatose, Tablettose. 
 
Functional Category: Tablet and Capsule diluent. 
 
Description: White to off-white crystalline particles powder, odorless. 
 
Solubility: Freely soluble in water, practically insoluble in chloroform, ethanol 
and ether. 
 
Structural Formula: 
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Applications:   As   filler   or   diluent   in   tablets (wet granulation and   direct 
compression) and capsules, in lyophilized products and infant fed formula 
 
Stability: Under humid conditions (80% RH and above) 
 
Storage conditions: Lactose should be stored in a well-closed  container in a 
cool, dry place. 
 
Incompatibilities:  A  Maillard-type  condensation  reaction  is  likely  to  occur 
between  lactose  and  compounds   with  a  primary  amine  group  to  form  
brown colored products. 
 
Safety: An adverse reaction to lactose is largely attributed to lactose intolerance, 
which occurs in persons with a deficiency of the intestinal enzyme lactase. 
 
 
 
 
 
5.1.6 TALC:  
Nonproprietary name: Purified talc 
 
Synonym: Powdered talc. 
     
Empirical formula: M g 6 (Si2O5)4(OH)4 
 
Description: Talc is very fine, white to greyish-white colored, odorless, hydrophobic, 
crystalline powder. It adheres readily to the skin, is soft to touch, and free from 
grittiness. 
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Functional category: Anticaking agent, glidant, tablet and capsule diluent, tablet 
and capsule lubricant 
 
Table No:2 Concentrations of talc to be used in various applications 
 
Use Concentration (%) 
Dusting powder 90-99 
Glidant and tablet lubricant 1-10 
Tablet and capsule diluents 5-30 
 
Stability and storage conditions: Talc is a stable material. It should be stored in 
a well-closed container in a cool, dry place. 
 
Incompatibilities:  Incompatible with quaternary ammonium compounds 
Safety: Following oral ingestion talc is not absorbed systemical ly and  may be  
thus regarded as an essentially nontoxic material 
 
Pharmaceutical applications: It is commonly used as lubricant in tablet and 
capsules. 
 
 
 
 
5.1.7 MAGNESIUM STEARATE: 
 
Synonyms: Magnesium octadecanoate; octadecanoic acid, magnesium salt, 
stearic acid. 
 
Empirical Formula : C36H70MgO4 
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Molecular weight : 91.3 
 
Structural Formula: CH3 (CH2)16COO) 
 
Functional Category: Tablet and capsule lubricant. 
 
Description: Magnesium stearate is a fine, white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and characteristic 
taste. The powder is greasy to the touch and readily adheres to the skin. 
 
Stability and storage conditions: Magnesium stearate is stable and should stored 
in a well closed container in a cool, dry place 
 
Incompatibilities: Incompatible with strong acids, alkalis, and iron salts. Avoid 
mixing with strong oxidizing materials. Magnesium stearate cannot be used in 
products containing aspirin, some vitamins, and most alkaloidal salt. 
 
Application: magnesium stearate used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily     used as a lubricant in capsule and tablet manufacture 
at concentrations between 0.25 %   and 5.0 w/w. It is also used in barrier creams. 
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5.1.8 ASPARTAME: 
 
Synonyms:(3S)-3-Amino-4-[[(1S)-1-benzyl-2-methoxy-2-oxoethyl]amino]-4- 
oxobutanoic acid. 
 
Nonproprietary Name: 
BP: Aspartame 
PhEur: Aspartame 
USP-NF: Aspartame 
 
Chemical Name: N-L-a-Aspartyl-L-phenylalanine 1-methyl ester 
 
Empirical Formula : C14H18N2O5 
 
Molecular Weight  : 294.30 
 
Description : Aspartame occurs as an off white, almost odorless crystalline powder 
with an intensely sweet taste 
 
Functional Category: Sweetening agent 
 
Stability and Storage Conditions: Aspartame is stable in dry conditions. In the 
presence of moisture, hydrolysis occurs to form the degradation products L-aspartyl-
L - phenylalanine and 3-benzyl-6-carboxymethyl-2,5-diketopiperazine with a 
resulting loss of sweetness   Stability in aqueous solutions has been enhanced by 
the addition of cyclodextrins,(4,5) and by the addition of  polyethylene glycol 400 at 
pH 2.(6) However, at pH 3.5–4.5 stability is not enhanced by the replacement of 
water with organic solvents. 
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Applications: Aspartame is used as an intense sweetening agent in beverage 
products, food products, and table-top sweeteners, and in pharmaceutical 
preparations including tablets (1, 2) powder mixes, and vitamin preparations. It 
enhances flavor systems and can be used to mask some unpleasant taste 
characteristics; the approximate sweetening power is 180–200 times that of 
sucrose. 
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6. MATERIALS & METHODS 
 
Table No: 3 Materials Used for Formulation of Diltiazem Hydrochloride 
 
 
 
 
Sl.No. Materials used Source 
1. Diltiazem Hydrochloride Pellsys pharma pvt limited, Hyderabad 
2. Croscarmellose sodium Vijlak Pharma Limited, Hyderabad 
 
3. Crospovidone Vijlak Pharma Limited,  Hyderabad 
 
4. Sodium starch Glycolate Vijlak Pharma Limited, Hyderabad 
 
5. Microcrystalline cellulose Vijlak Pharma Limited, Hyderabad 
 
6. Magnesium Stearate Oxford Laboratory, Mumbai. 
7. Talc NR Chem, Mumbai. 
8. Lactose Merck Specialties’  limited., Mumbai 
9. Aspartame Provizer Pharma, Hyderabad 
10. Menthol Sagar Aromatics, Mumbai 
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Table No:4 Equipment Used for Formulation of Diltiazem Hydrochloride 
 
Sl. No. Equipment Make / Model 
 
1. 
 
Tablet compression machine 
Rimek, minipress 10 station rotary 
machine 
 
2. 
 
Hardness tester 
Monsanto hardness tester, 
Servewell instruments and 
equipments pvt. ltd., Bangalore. 
3. Friability Test Apparatus Classic Scientific , Maharastra 
 
4. 
Tablet Dissolution Test 
Apparatus 
Electrolab  Dissolution  Apparatus, 
Mumbai 
 
5. 
UV visible spectrophotometer PG Instruments limited, T-80 UV-
VIS Spectrometer 
 
6. 
Digital Balance Shimadzu, Shimadzu corporation, 
Japan 
7. pH meter Hanna Instruments, Ranchi. 
8. FT-IR Spectrometer Perkin Elmer Instruments, USA 
 
 
 
6.1 Drug-Excipient Compatibility study (FTIR)57: 
 
The study was designed to determine compatibility of drug with different co-
processed excipients. Completely dried KBR and samples (drug and excipients) 
taken in 9:1 ratio and grinded for proper mixing. Sample was filled into the holes of 
stainless steel disk and sandwiched in the hydraulic press until pressure reaches 
20,000 psi. After few seconds, pressure was released and pellet was collected. 
Then the pellet was inserted into the sample holder and run for the spectrum. FTIR 
48 
 Department of Pharmaceutics, E.G.S.Pillay College of Pharmacy, Nagapattinam. 
spectra of pure drug and excipients separately done to determine the compatibility. 
FTIR spectra of drug and excipients were obtained .The spectra were scanned over 
the wave number range of4000-400 cm-1. 
 
 6.2. ANALYTICAL METHODS: 
 
Preparation of   pH 6.8 phosphate buffer57: 
Dissolve 28.80 g of disodium hydrogen phosphate and 11.45 g of potassium 
dihydrogen phosphate in sufficient water to produce 1000 ml57. 
 
Preparation of Calibration Curve of Diltiazem HCl in pH 6.8 phosphate buffer: 
100mg of Diltiazem HCl was weighed accurately and dissolved in pH 6.8 phosphate 
buffer, which resulted in 1000 µg/ml. Then from the stock solution 100 µg/ml 
solution was prepared from this 2, 4, 6, 8, 10 µg/ml were prepared. The 
absorbances of the above dilutions were measured using UV-spectrophotometer at 
236 nm using 6.8 pH phosphate buffer as blank. The conc. of corresponding 
absorbance was given below table. Standard curve was plotted by taking 
concentration on x-axis and absorbance on y-axis57. The results are given in table-5 
and figure-1 
Table No:5 Standard calibration curve of Diltiazem Hydrochloride in pH 6.8 
phosphate buffer 
Sl.No Concentration mcg/ml Absorbance at 236nm 
 
 
 
 
 
1. 2 0.054 
2. 4 0.101 
3. 6 0.154 
4. 8 0.205 
5. 10 0.254 
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FigureNo:1 Calibration Curve of Diltiazem HCl in pH 6.8 phosphate buffer 
B) PREPARATION OF DILTIAZEM HYDROCHLORIDE FAST DISSOLVING 
TABLET58 
Diltiazem Hydrochloride fast dissolving tablet DLTF1 to DLTF9 were 
prepared by direct compression method and the detailed tablet composition was 
given in table-1. A total of tablets were prepared in every batch and the quantity 
for 60 tablets. 
Method: 
 All the ingredients were passed through 60 mesh sieve 
separately. 
 Then drug and diluents separately taking small portion of both 
each time and blending it thoroughly to get uniform mixture. 
 The granules were compressed using 8 mm size to get a tablet 
of 160 mg tablet weight using Rimek mini press machine 
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 Table No:6 Materials used in the study with their property 
Sl.No 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No. 
Materials Property 
 
 
1. Diltiazem Hydrochloride Antihypertensive 
 2. Crospovidone Disintegrants 
 3. Croscarmellose sodium Disintegrants 
4. Sodium starch glycolate Disintegrants 
5. Microcrystalline cellulose Diluents 
6. Lactose Diluents 
7. 
7. 
Talc Glidant 
8. Magnesium  stearate Lubricant 
9. Aspartame Sweetening  agent 
10. Menthol Flavouring agent 
 
Table No:7 Parameters fixed for the Fast Dissolving Tablets 
Sl. No. Test Limit 
1. Physical 
appearance 
white, circular 
2. Diameter 7 mm 
3. Thickness 3mm 
4. Hardness 2-4 Kg 
5. Friability NMT 1% 
6. Disintegration time NMT 180 Sec 
  
 
C) PRECOMPESSION STUDY46, 47, 48: 
Angle of repose (θ) 46,48:- 
Angle of repose is defined as the maximum angle possible between the 
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surface of a pile of the powder and horizontal plane. The frictional force in a loose 
powder or granules can be measured by angle of repose. 
 
tan θ =h/r 
θ = tan-1h/r 
Where, 
θ  is the angle of repose, 
h is height of pile 
r is radius of the base of pile 
Different ranges of flow ability in terms of angle of repose (Table No. 9) are 
given below. 
 
Table No:8 Relationship between angle of repose (θ) and flow properties. 
Angle of Repose (θ)  Flow 
<25 
 
25-30 
 
30-40 
 
>40 
  Excellent  
 
  Good 
 
  Passable or poor 
 
 
Method: 
A funnel was filled to the brim and the test sample was allowed to flow 
smoothly through the orifice under gravity. From the cone formed on a graph 
sheet was taken to measure the area of pile, thereby evaluating the flow ability of 
the granules. Height of the pile was also measured. 
 
Bulk density:- 
Bulk density  is  defined  as  the  mass  of  a  powder  divided  by  the  bulk 
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volume.   The  bulk  density  of  a  powder  depends  primarily  on  particle  size 
distribution, particle shape, and the tendency of the particles to adhere  to one 
another. 
 
Method: 
Both  loose  bulk  density  (LBD)  and  tapped  bulk  density  (TBD)  were 
determined. A quantity of accurately weighed powder (bulk) from each formula, 
previously shaken to break any agglomerates formed was introduced into a 25 ml 
measuring cylinder.  After the initial volume was observed, the cylinder was 
allowed to fall under its own weight onto a hard surface from the height of 2.5 cm 
at 2 sec interval. The tapping was continued until no further change in volume was 
noted. The LBD and TBD can be calculated using following formula, 
  
Weight of powder 
LBD = --------------------------------------------         ………   (a) 
  Volume of powder before tapping 
 
Weight of powder 
TBD = --------------------------------------------         ………   (b) 
  Volume of powder after tapping  
 
POST-COMPRESSION PARAMETERS: 
 
All the formulation of Diltiazem Hydrochloride prepared were evaluated for 
the following physical and chemical parameters 
 
Physical Parameters:- 
 
Size and shape: The tablet formulated was circular in shape with 7 mm diameter. 
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Organoleptic Characters:- 
Colour: Diltiazem Hydrochloride fast dissolving tablets were found to be white in 
colour. 
 
TABLET PROPERTIES: 
 
Hardness test: 
 
Tablets require a certain amount of strength, or hardness and resistance to 
friability, to withstand mechanical shocks of handling in manufacture, packaging 
and shipping.  The hardness  o f  the  tab le ts  was  de te rm ined  u s i n g  
Monsanto  Hardness tester. It is expressed in Kg/cm2. Three tablets were 
randomly picked from each formulation a n d  t h e  m e a n  a n d  s t a n d a r d  
d e v i a t i o n    values w e r e  calculated. 
 
Friability test:- 
It is the phenomenon whereby tablet surfaces are damaged and/or show 
evidence  of  lamination  or  breakage  when  subjected  to  mechanical  shock  or 
attrition. 
 
The friability of tablets was determined by using Veego Friabilator. It is 
expressed in percentage (%). Twenty tablets were initially weighed (Winitial) and 
transferred into friabilator. The friabilator was operated at 25 rpm for 4 minutes or 
run up to 100 revolutions. The tablets were weighed again (Wfinal). The 
percentage friability was then calculated by, 
   
Initial weight - Final weight   
F= --------------------------------------- X 100   ………… (d) 
   Intial weight    
Friability of tablets less than 1% is considered acceptable. 
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Weight variation test49:- 
 
The tablets were selected randomly from each formulation and weighed 
individually to check for weight variation. The U.S Pharmacopoeia allows a little 
variation in the weight of a tablet. The following percentage deviation in weight 
variation is allowed. 
 
 
Table No:9 Percentage deviation in weight variation 
 
 
 
 
 
 
 
 
In all the formulations the tablet weight was more than130mg and less 
than 324 mg, hence 7.5% maximum difference allowed. 
Drug Content Uniformity:  
Five tablets were weighed and crushed with pestle in a mortar. The fine 
powder was weighed to get a100mg (equivalent to 60mg Diltiazem HCl) and 
transferred to 250 ml conical flask containing 100 ml of 6.8 pH phosphate buffer 
stirred for 45 min in an sonicator then the solution was filtered and it was analyzed 
by UV spectrophotometrically at 236 nm and drug content was determined. 
 
Disintegration Time:  
Disintegration time is the time required for a tablet to break into granules of 
specified size (or smaller), under carefully specified test conditions. Six tablets were 
placed in each of the tubes and run the apparatus using phosphate buffer 6.8 pH 
which is maintained at 37±2 ºC. The time required for complete passage of tablet 
Average weight of a tablet Percentage 
deviation 
130 mg or less 
 
More than 130 mg and less than 324 mg 
 
324 mg or more 
10 
 
7.5 
 
5 
55 
 Department of Pharmaceutics, E.G.S.Pillay College of Pharmacy, Nagapattinam. 
fragments through the sieve #10 was considered as the disintegration time of the 
tablet. 
In-vitro dissolution Studies:  
The release rate of Diltiazem HCl tablets was determined using USP 
Dissolution type II testing apparatus (paddle type). One tablet was placed in each of 
the six dissolution flasks containing 900 ml of dissolution medium previously 
maintained at 37 ± 0.5ºC and at 50 rpm. After completion of each specified time 
interval, aliquots of 5ml was withdrawn from the dissolution media and the samples 
were replaced with fresh dissolution medium. After filtration and samples are diluted 
and absorbance was noted at 236 nm using UV visible spectrophotometer and 
percentage of drug release was calculated. 
 
In vitro drug release studies details: 
 
Apparatus used : Dissolution test apparatus (type II) 
Dissolution medium : pH 6.8 phosphate buffer  
Dissolution medium 
 Volume : 900ml  
Temperature : 37 ±0.5°C 
Speed of basket paddle: 50 rpm  
Sampling intervals : 1 min  
Sample withdraw : 5 ml  
Absorbance measured : 236 nm 
Drug polymer interaction studies: FTIR STUDIES: 
IR spectra for pure drug, formulations Diltiazem Hydrochloride, 
Crospovidone and DLTF6 were   recorded   in   a   Fourier   transform   infrared   
(FTIR)   spectrophotometer with KBr pellets. 
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Table No: 10 Formulation of Diltiazem Hydrochloride Fast Dissolving Tablets 
Prepared By Direct Compression Method 
Ingredients (mg) DLTF1 DLTF2 DLTF3 DLTF4 DLTF5 DLTF6 DLTF7 DLTF8 DLTF9 
Diltiazem Hydrochloride 
 
20 20 20 20 20 20 20 20 20 
Croscarmellose sodium 
 
1.6 4.8 8.0 ---- ---- ---- ---- ---- ---- 
Crospovidone ---- ---- ---- 3.2 6.4 8.0 ---- ---- ---- 
Sodium starch glycolate ---- ---- ---- ---- ---- ---- 6.4 9.6 12.8 
Microcrystalline cellulose 48.8 44.8 42.4 47.4 44 45.6 44 41.6 37.6 
Lactose 80 80 80 80 80 80 80 80 80 
Talc 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 
Mg stearate 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 
Aspartame 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 3.2 
Menthol 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 
Total weight in (mg) 160 160 160 160 160 160 160 160 160 
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Table No:11 Formulation of Diltiazem Hydrochloride Fast Dissolving Tablets 
Prepared By Direct Compression Method (For 60 Tablets) 
 
 
 
 
 
 
Ingredients (mg) DLTF1 DLTF2 DLTF3 DLTF4 DLTF5 DLTF6 DLTF7 DLTF8 DLTF9 
Diltiazem 
Hydrochloride 
1200 1200 1200 1200 1200 1200 1200 1200 1200 
Croscarmellose  
sodium 
 
96 288 480 ---- ---- ---- ---- ---- ---- 
Crospovidone ---- ---- ---- 192 384 480 ---- ---- ---- 
Sodium starch  
glycolate 
---- ---- ---- ---- ---- ---- 384 576 768 
Microcrystalline  
cellulose 
3120 2928 2736 3030 2832 2736 2832 2640 2448 
Lactose 4800 4800 4800 4800 4800 4800 4800 4800 4800 
Talc 192 192 192 192 192 192 192 192 192 
Magnesium  
stearate 
192 192 192 192 192 192 192 192 192 
Menthol 3 3 3 3 3 3 3 3 3 
Total weight in 
(mg) 
9600 9600 9600 9600 9600 9600 9600 9600 9600 
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7. RESULTS AND DISCUSSION 
 
RESULTS: 
PRE-FORMULATION STUDIES: 
SOLUBILITY:It is soluble in water, methanol and chloroform.  
MELTING POINT: 2620 C 
 
 7.1 Results of Granule Parameter Evaluation: 
 
Table No:12 Granule Parameters for Diltiazem Hydrochloride Formulation  
 
 
 
 
 
Formulation 
Code 
Bulk 
Density gm/cc 
 
 Tapped Density 
Angle of 
Repose θ=h/r 
Percentage 
Porosity 
DLTF1 0.53 1.27 28.32 56 
DLTF2 0.52 1.45 29.08 57 
DLTF3 0.55 1.23 30.21 56 
DLTF4 0.54 1.09 30.11 56.5 
DLTF5 0.51 1.23 28.43 57 
DLTF6 0.50 1.87 30.38 56.8 
DLTF7 0.53 1.45 31.03 56.9 
DLTF8 0.54 1.78 28.10 56 
DLTF9 0.52 1.67 26.28 56.4 
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 7.2 Hardness Test Result 
Table No:13 Hardness Test for Diltiazem Hydrochloride Formulation 
Formulation code Hardness in* Kg/cm2 ±SD 
DLTF1 3.2±0.12 
 
 
DLTF2 3.23 ±0.28 
DLTF3 3.34 ±0.12 
DLTF4 3.23 ±0.24 
DLTF5 2.9 ±0.36 
DLTF6 2.8±0.32 
DLTF7 3.1±0.12 
DLTF8 2.91 ±0.01 
DLTF9 2.95 ±0.14 
* Average of three determinations 
 
 7.3 Friability Test Results 
Table No:14 Friability test for Diltiazem Hydrochloride Formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation code Friability (%) 
DLTF1 0.64 
DLTF2 0.66 
DLTF3 0.67 
DLTF4 0.62 
DLTF5 0.5 
DLTF6 0.59 
DLTF7 0.53 
DLTF8 0.62 
DLTF9 0.61 
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7.4 In Vitro Dispersion Time  
Table No:15 In Vitro Dispersion Time for Diltiazem Hydrochloride 
Formulation 
 
 
 
 
 
 
Formulation code Time in seconds ±SD 
DLTF1 75.0±2.5 
DLTF2 60.0±1.4 
DLTF3 35.0±1.8 
DLTF4 55.0±0.7 
DLTF5 38.0±0.4 
DLTF6 15.0±0.5 
DLTF7 110.0±1.1 
DLTF8 85.0±1.4 
DLTF9 68.0±0.7 
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Table No:16 Weight Variation of Diltiazem Hydrochloride Formulation 
Sl.No DLTF1 DLTF2 DLTF3 
Weight in 
mgs 
Difference 
in weight 
Percent 
Deviation 
Weight in 
mgs 
Difference in 
weight 
Percent 
Deviation 
Weight in 
mgs 
Difference in 
weight 
Percent 
Deviation 
1 161 1.3 0.81 164 4.4 2.7 163 2.2 1.36 
2 162 2.3 1.4 162 2.4 1.49 162 1.2 0.74 
3 159 0.7 0.43 158 2.4 1.49 162 1.2 0.74 
4 164 4.3 2.69 160 0.4 0.24 160 0.8 0.49 
5 157 2.7 1.69 158 2.4 1.49 160 0.8 0.49 
6 158 1.7 1.06 158 2.4 1.49 163 2.2 1.36 
7 160 0.3 0.187 159 1.4 0.87 162 1.2 0.74 
8 158 1.7 1.06 160 0.4 0.24 159 1.8 1.11 
9 160 0.3 0.187 162 2.4 1.49 157 3.8 2.36 
      10 158 1.7 1.06 163 3.4 2.11 160 0.8 0.49 
 Average of 10 Tablets 159.7 mg Average of 10 Tablets 160.4 mg Average of 10 Tablets 160.8mg 
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Table No:17 Weight Variation of Diltiazem Hydrochloride Formulation 
 
 
Sl. No 
DLTF4 DLTF5 DLTF6 
Weight in 
mgs 
Difference 
in weight 
Percent 
Deviation 
Weight in 
mgs 
Difference in 
weight 
Percent 
Deviation 
Weight in 
mgs 
Difference in 
weight 
Percent 
Deviation 
1 160 1.1 0.68 160 0.7 0.43 162 0.8 0.49 
2 165 4.1 2.54 162 1.3 0.80 163 1.8 1.11 
3 158 2.9 1.80 164 3.3 2.05 161 0.2 0.12 
4 160 0.9 0.55 162 1.3 0.80 162 0.8 0.49 
5 162 1.1 0.68 162 1.3 0.80 162 0.8 0.49 
6 163 2.1 1.30 161 0.3 0.18 163 1.8 1.11 
7 163 2.1 1.30 159 1.7 1.05 158 3.2 1.98 
8 157 3.9 2.42 158 2.7 1.68 159 2.2 1.36 
9 159 1.9 1.18 157 3.7 2.30 160 1.2 0.74 
10 160 0.9 0.55 162 1.3 0.80 162 0.8 0.49 
 Average of 10 Tablets160.9 mg Average of 10 Tablets 160.7mg Average of 10 Tablets161.2 mg 
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Table No:18 Weight Variation of Diltiazem Hydrochloride Formulation 
 
Sl. No DLTF7 DLTF8 DLTF9 
Weight in 
mgs 
Difference  
in weight 
Percent 
Deviation 
Weight   
in mgs 
Difference    
in weight 
Percent 
Deviation 
Weight   
in mgs 
Difference    
in weight 
Percent 
Deviation 
1 161 0.8 0.49 160 0.1 0.06 162 1.3 0.80 
2 162 1.8 1.12 159 1.1 0.68 163 2.3 1.43 
3 163 2.8 1.74 157 3.1 1.93 159 1.7 1.05 
4 159 1.2 0.74 162 1.9 1.18 158 2.7 1.68 
5 158 2.2 1.37 163 2.9 1.81 162 1.3 0.80 
6 157 3.2 1.99 159 1.1 0.68 163 2.3 1.43 
7 159 1.2 0.74 157 3.1 1.93 158 2.7 1.68 
8 160 0.2 0.12 159 1.1 0.68 159 1.7 1.05 
9 161 0.8 0.49 163 2.9 1.81 161 0.3 0.18 
10 162 1.8 1.12 162 1.9 1.18 162 1.3 0.80 
 Average of 10 Tablets 160.2 mg Average of 10 Tablets 160.1 mg Average of 10 Tablets 160.7 mg 
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Figure No:2 IR Spectrum of Pure Drug Diltiazem Hydrochloride 
 
 
IR Spectrum of Pure Drug Diltiazem Hydrochloride 
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Figure No:3 IR Spectrum of Formulation DLTF6 
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Table No:19 Drug Content of Diltiazem Hydrochloride Formulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sl. No. 
 
Formulation code 
Average Content (%) 
± SD 
1 DLTF1 99.5 ± 0.175 
2 DLTF2 100.0 ± 0.275 
3 DLTF3 97.0 ± 0.175 
4 DLTF4 96.0 ± 0.436 
5 DLTF5 99.3 ± 0.354 
6 DLTF6 99.0 ± 0.154 
7 DLTF7 95.5 ± 0.265 
8 DLTF8 99.5 ± 0.241 
9 DLTF9 97.0 ± 0.156 
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Table No:20 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF1 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure No:4 In-vitro Drug Release of Diltiazem Hydrochloride Fast Dissolving Tablet 
DLTF1 
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Time in minutes 
Time in Minute % Drug Release   ± SD 
01 15.3 ± 0.12 
02 27.0 ± 0.32 
03 39.78 ± 0.12 
04 48.95 ± 0.32 
05 60.12 ± 0.21 
06 72.90 ± 0.16 
07 81.9 ± 0.55 
08 91.8 ± 0.34 
09 94.5 ± 0.16 
10 97.02 ± 0.44 
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Table No:21 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure No:5 In-vitro Drug Release of Diltiazem Hydrochloride Fast Dissolving Tablet 
DLTF2 
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Time in Minute %Drug Release ±SD 
01 14.4 ± 0.12 
02 28.8 ± 0.34 
03 39.6 ± 0.56 
04 48.24 ± 0.45 
05 61.2 ± 0.66 
06 72.0 ± 0.68 
07 82.8 ± 0.43 
08 93.6 ± 0.12 
09 97.02 ± 0.13 
10 98.1 ± 0.01 
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Table No:22 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF3 
 
Time in Minute %Drug Release  ±SD 
01 16.56 ± 0.32 
02 34.2 ± 0.12 
03 47.16 ± 0.32 
04 57.78 ± 0.44 
05 75.60 ± 0.45 
06 84.42 ± 0.43 
07 95.58 ± 0.23 
08 98.82 ± 0.72 
09 98.82 ± 0.12 
10 98.82 ± 0.10 
 
 
 
Figure No:6 In-vitro Drug Release of Diltiazem Hydrochloride Fast Dissolving Tablet 
DLTF3 
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Table No:23 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF4 
 
 
 
 
Time In Minute 
% Drug Release 
±SD 
01 20.66 ± 0.22 
02 41.58 ± 0.23 
03 57.78 ± 0.55 
04 72.0 ± 0.45 
05 82.80 ± 0.88 
06 86.76 ± 0.12 
07 90.00 ± 0.14 
08 93.60 ± 0.16 
09 95.40 ± 0.24 
10 97.74 ± 0.12 
 
 
 
 
Figure No:7 In-vitro Drug Release of Diltiazem Hydrochloride Fast Dissolving Tablet 
DLTF4 
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Table No:24 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF5 
 
 
 
 
Time in Minute 
% Drug Release ±SD 
01 21.78 ± 0.22 
02 41.94 ± 0.23 
03 59.94 ± 0.22 
04 73.62 ± 0.36 
05 83.16 ± 0.24 
06 88.38 ± 0.14 
07 91.98 ± 0.16 
08 95.22 ± 0.18 
09 96.3 ± 0.16 
10 98.46 ± 0.01 
 
 
 
 
Figure No:8 In-vitro Drug Release of Diltiazem Hydrochloride Fast Dissolving Tablet 
DLTF5 
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Table No:25 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF6 
 
 
 
Time in Minute 
% Drug Release ±SD 
01 25.92±0.44 
02 52.02±0.46 
03 74.52±0.12 
04 82.56±0.5 
05 89.12±0.8 
06 
 
 
 
 
91.78±1.0 
07 93.24±0.11 
08 99.9 ±0.00 
 
 
 
 
 
  
FigureNo:9 In-vitro Drug Release of Diltiazem Hydrochloride Fast 
Dissolving Tablet DLTF6 
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Table No:26 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF7 
 
 
Time in Minute 
% Drug Release ±SD 
01 13.86 ± 0.13 
02 26.10 ± 0.43 
03 43.74 ± 0.65 
04 55.80 ± 0.24 
05 58.86 ± 0.64 
06 63.90 ± 0.12 
07 75.96 ± 0.24 
08 88.92 ± 0.42 
09 93.24 ± 0.31 
10 94.14 ± 0.52 
 
 
  
 
Figure No:10 In-vitro Drug Release of Diltiazem Hydrochloride Fast Dissolving 
Tablet DLTF7 
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Table No:27 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF8 
 
 
 
Time in Minute 
% Drug Release 
±SD 
01 11.88 ± 0.78 
02 23.94 ± 0.64 
03 34.74 ± 0.44 
04 47.16 ± 0.22 
05 56.52 ± 0.42 
06 68.04 ± 0.12 
07 79.38 ± 0.14 
08 85.86 ± 0.16 
09 91.08 ± 0.99 
10 94.68 ± 0.11 
 
 
 
Figure No:11 In-vitro Drug Release of Diltiazem Hydrochloride Fast Dissolving 
Tablet DLTF8 
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Table No:28 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF9 
 
 
 
Time in Minute 
% Drug Release ±SD 
01 12.96 ± 0.33 
02 25.92 ± 0.36 
03 41.76 ± 0.23 
04 53.64 ± 0.12 
05 68.04 ± 0.12 
06 79.38 ± 0.24 
07 89.82 ± 0.16 
08 93.78 ± 0.18 
09 94.32 ± 0.03 
10 95.08 ± 0.03 
 
 
 
 
Figure No:12 In-vitro Drug Release of Diltiazem Hydrochloride Fast Dissolving 
Tablet DLTF9 
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Table No:29 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving Tablet 
DLTF1 to DLTF9 
 
 
 
Time DLTF1 
(%) 
DLTF2 
(%) 
DLTF3 
(%) 
DLTF4 
(%) 
DLTF5 
(%) 
DLTF6 
(%) 
DLTF7 
(%) 
DLTF8 
(%) 
DLTF9 
(%) 
1 
 
15.3±0.1
2 
14.4±0.1
2 
16.56±0
.32 
20.66±0
.22 
21.78±0.
22 
25.92±0.
44 
13.86±0.
13 
11.880
78 
12.96±0
.33 
2 27.0±0.3
2 
28.8±0.3
4 
34.2 
±0.12 
41.58±0
.23 
41.94±0.
23 
52.02±0.
46 
26.10±0.
43 
23.940.
64 
25.92±0
.36 
3 39.78±0.
12 
39.6±0.5
6 
47.16±0
.32 
57.78±0
.55 
59.94±0.
22 
74.52±0.
12 
43.74±0.
65 
34.74±
0.4 
41.76±0
.23 
4 48.95±0.
32 
48.24±0.
4 
57.78±0
.44 
72.0±0.
45 
73.62±0.
36 
82.56±0.
5 
55.80±0.
24 
47.16±
0.2 
53.64±0
.12 
5 60.12±0.
21 
61.2±0.6
6 
75.60±0
.45 
82.80±0
.88 
83.16±0.
24 
89.12±0.
8 
58.86±0.
64 
56.52±
0.4 
68.04±0
.12 
6 72.90±0.
16 
72.0±0.6
8 
84.42±0
.43 
86.76±0
.12 
88.38±0.
14 
91.78±1.
0 
63.90±0.
12 
68.04±
0.1 
79.38±0
.24 
7 81.9±0.5
5 
82.8±0.4
3 
95.58±0
.23 
90.00±0
.14 
91.98±0.
16 
93.24±0.
11 
75.96±0.
24 
79.38±
0.1 
89.82±0
.16 
8 91.8 
±0.34 
93.6±0.1
2 
98.82±0
.72 
93.60±0
.16 
95.22±0.
18 
99.9 ±0. 
00 
88.92±0.
42 
85.86±
0.1 
93.78±0
.18 
9 94.5±0.1
6 
97.02±0.
1 
98.82±0
.12 
95.40±0
.24 
96.3±0.1
6 
99.9 ±0. 
00 
93.24±0.
31 
91.08±
0.9 
94.32±0
.03 
10 97.02±0.
44 
98.1±0.0
1 
98.82±0
.10 
97.74±0
.12 
98.46±0.
01 
99.9 ±0. 
00 
94.14±0.
52 
94.68±
0.1 
95.08 ± 
0.03 
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Figure No:13 In-vitro Drug Release of Diltiazem Hydrochloride Fast dissolving 
Tablet DLTF1 to DLTF9 
 
 
 
 
 
Table No:30 Time required to dissolve 70% of the drug with various Diltiazem 
Hydrochloride fast dissolving tablet 
 
Sl. No Formulation Code T70%(min) 
1 DLTF1 4.3 
2 DLTF2 4.5 
3 DLTF3 4.4 
4 DLTF4 3.8 
5 DLTF5 3.4 
6 DLTF6 
 
2.8 
7 DLTF7 6.3 
8 DLTF8 6.5 
9 DLTF9 5.9 
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DISCUSSION 
 
Diltiazem Hydrochloride is an angiotensin II receptor antagonist and is used for 
treatment of essential Hypertension. Croscarmellose sodium, Crospovidone and Sodium 
starch glycolate were used in different concentration to prepare Fast dissolving tablets. 
 
All  the formulations   prepared   were   evaluated   for   precompression 
parameters  like  Bulk  density,  Tapped  density,  Angle  of  Repose  and  Percentage 
porosity  and are given in table. The angle of repose for all formulation was found to be 
less than 30° indicating free flowing granules. All the Fast dissolving tablets were found 
to be elegant without any chipping, capping and sticking. 
 
Fast dissolving tablets so prepared were evaluated for post-compression 
parameters like Hardness, Friability, Drug content uniformity, weight variation, In-Vitro 
Dispersion, and In -Vitro Drug re lease s tud ies . Hardness of the three tablets of each 
batch was checked by using Monsanto hardness tester. The results showed that the 
hardness of the tablet is in the 2.8-4.0.Kg/cm2. Tablets of each batch were evaluated 
for percentage friability. The results suggest that the friability will withstand the rigors 
which occurred during packing, transportation and shipping etc. Because of their low 
percentage friability is less than one. 
 
Drug content uniformity study was carried out on the tablets of every batch. The 
results were showed that there was uniform distribution of the drug throughout the batch. 
 
Drug Polymer Interaction Study:  
The probability/possibility of drug polymer interaction was studied by Infrared 
Spectroscopy using KBr pellet method. The Infrared Spectra of Pure drug Diltiazem 
Hydrochloride  shows  a  characteristics  peak  at  different  frequencies  which  are  as 
follows. 
 Peak at 1667.24cm-1 is due to C=O stretching. 
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 Peak at 1422 cm-1 is due to C=N stretching. 
 
 Peak2957.79cm-1 is due to C-H stretching. 
 
 Peak at 1582.76 cm-1 is due to C=C stretching. 
 
The spectra of the formulation scanned showed following peaks. 
 
 Peak at 1661.73 cm-1 is due to C=O stretching. 
 
 Peak at 1438.25 cm-1 is due to C=N stretching. 
 
 Peak at 2976.52 cm-1 is due to C-H stretching. 
 
When the peaks of the formulation spectra compared with the peak of 
Diltiazem Hydrochloride Pure Drug Spectra, the characteristic peak of Pure Drug were 
retained indicating the intactness of the drug in the formulation prepared. 
 
Tablets of every batch were subjected to weight variation test, difference in 
weight and percent deviation was calculated for each tablet. The average  weight  of  
the  tablet  is  approximately  160mg  and  it  is  in between 80 - 320mg. So the 
permissible limit is ± 7.5%. The results of the test showed that, the tablets were 
weighing in the range of limit. 
 
Three tablets of each batch were evaluated for In-Vitro Dispersion time test.  
The  results  showed  that  the  tablets  so  prepared  were  disintegrating  and dispersing 
in  the time range of 15 to 110 seconds. The tablets of the batch DLTF6 prepared 
using 8mg of Crospovidone showed Faster disintegration is within 15 seconds. 
 
Finally, the tablets were evaluated for In-Vitro drug release studies for a period 
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of 10 minutes and the results were shown in the table 17-28. In all the cases a minimum 
of 91% of the drug was released within 10 minutes, among the various formulation 
prepared  the batch/tablets of the composition drug Diltiazem Hydrochloride and 
Crospovidone (8mg) DLTF6  released 99% of the drug within 8 minute. 
 
The  improved  drug  release  was  mainly  due  to  the  increased  In-Vitro 
dispersion which is due to the addition /inclusion of super disintegrant.  t70% value of 
the drug was released within a minimum time of 3 minutes. 
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8. SUMMARY 
 
 In some cases of Hypertension Quick onset of action is desired, the Fast 
dissolving tablets plays a vital role.  Fast dissolving tablets have much number of 
advantages   over   the   conventional   tablets   like   rapid   disintegration,   faster 
dissolution, Ease of administration and quick onset of action etc. 
 
 In  the  present  research  work,  Diltiazem Hydrochloride Fast  dissolving  tablets  
were prepared using Super disintegrants like Croscarmellose sodium, 
Crospovidone and Sodium  starch  Glycolate  in  different  concentrations  by  
Direct  Compression method. 
 
 Diltiazem Hydrochloride Fast dissolving Tablets prepared were evaluated for Pre- 
compressional   and   Post-compressional   parameters.   The   Pre-compressional 
parameters evaluated are bulk density, true density, angle of repose and percent 
porosity; where the angle of repose of all the formulations is below 30o indicating 
free flowing. 
 
 Post-compression parameters  l i ke  Hardness,  weight  variation,  Percent 
friability,  In-Vitro dispersion, Drug content uniformity and In-vitro drug release 
studies were  carried out for all the formulation. All the Formulation given the 
result within the official limits. 
 
 The drug and excipients interaction study is carried out by taking Infrared 
Spectrum of Pure drug and Best formulation (DLTF6). There is no change in 
the structure indicating drug is in intact form. 
 
 Formulation   DLTF6  in   which   Crospovidone   (8mg)   used,  shows   less 
Dissolution time i.e. 15 seconds and highest Dissolution rate 99.9% release in 8 
minutes which is considered as Formulation among all. 
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9. CONCLUSION 
 
The concepts of formulating Fast Dissolving Tablets of Diltiazem Hydrochloride 
offers a   suitable    practical   approach   in   serving   desired   objectives   of   faster 
disintegration and dissolution characteristics. 
 
In the present work, Fast dissolving tablets of Diltiazem Hydrochloride were 
prepared by Direct Compression Technique using Crospovidone, Croscarmellose 
Sodium starch glycolate as Super disintegrants.  All the Fast dissolving tablets of 
Diltiazem Hydrochloride prepared were subjected to Drug content Uniformity, weight 
variation, Hardness, Thickness, Friability, Disintegration and Dissolution studies. 
 
 Precompression parameters l ike  Bulk  density, Tapped dens i t y , 
pe rcen ta ge  Porosity, Angle of repose. The result of angle of repose indicates 
free flowing characteristics of granules. 
 
 Hardness of the tablet of every batch was in the range of 2.8 to 4.0Kg/cm2 
 
 Friability of all the tablets was less than 1%. 
 
 Weight variation test results of every batch showed that the weight of each 
tablet of the batch tested was within the range ±7.5%. 
 
 All the tablets formulated using Croscarmellose sodium, Crospovidone and 
Sodium starch glycolate disintegrated within 3minutes fulfilling the official limits 
of the Fast dissolving tablets. 
 
 IR Spectral analysis suggests that the characteristic peaks of the Pure drug 
Diltiazem Hydrochloride  exist  in  the  Spectra  of  Formulation  prepared  
indicting  the intactness of the drug is in intimate contact with the additives. It 
has not undergone any chemical interaction with t h e  exc ip ien ts  used  in  
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t he  development of Diltiazem Hydrochloride Fast dissolving tablets. 
 
 Drug content uniformity study results showed that the drug Diltiazem 
Hydrochloride was uniformly distributed throughout the formulation of every 
batch. 
 
 t70% value that is the time required /taken to the release 70% of the drug 
were determined for every batch, the formulation DLTF6   shows every low 
t70% i.e. 2.6minutes to release 70% of the drug. 
 
 Finally, we can conclude that, among various formulations prepared, the Fast    
dissolving   tablets   prepared,   using   Crospovidone   (8mg)   DLTF6, 
disintegrated rapidly and gave highest dissolution of Diltiazem Hydrochloride 
within a short period of time. 
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